CN116120461B - Novel anti-drug antibodies and uses thereof - Google Patents
Novel anti-drug antibodies and uses thereof Download PDFInfo
- Publication number
- CN116120461B CN116120461B CN202310093475.9A CN202310093475A CN116120461B CN 116120461 B CN116120461 B CN 116120461B CN 202310093475 A CN202310093475 A CN 202310093475A CN 116120461 B CN116120461 B CN 116120461B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence shown
- hcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 229940079593 drug Drugs 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 19
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 19
- 239000002157 polynucleotide Substances 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1026
- 230000027455 binding Effects 0.000 claims description 395
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 123
- 210000004027 cell Anatomy 0.000 claims description 107
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 104
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 104
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 102
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 101
- 241000282414 Homo sapiens Species 0.000 claims description 75
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 69
- 239000013598 vector Substances 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 12
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 210000003567 ascitic fluid Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 230000004068 intracellular signaling Effects 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 102000004243 Tubulin Human genes 0.000 claims description 4
- 108090000704 Tubulin Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000004910 pleural fluid Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 239000012624 DNA alkylating agent Substances 0.000 claims description 3
- 229940126161 DNA alkylating agent Drugs 0.000 claims description 3
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100021317 Inducible T-cell costimulator Human genes 0.000 claims description 3
- 208000002151 Pleural effusion Diseases 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 239000012642 immune effector Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 238000002732 pharmacokinetic assay Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 317
- 108091007433 antigens Proteins 0.000 description 317
- 102000036639 antigens Human genes 0.000 description 317
- 239000012634 fragment Substances 0.000 description 255
- 206010028980 Neoplasm Diseases 0.000 description 54
- 238000006467 substitution reaction Methods 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 29
- 125000000539 amino acid group Chemical group 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 18
- 239000012636 effector Substances 0.000 description 18
- -1 fccRI Chemical compound 0.000 description 18
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 150000007523 nucleic acids Chemical group 0.000 description 16
- 230000009870 specific binding Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 13
- 230000001588 bifunctional effect Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000013595 glycosylation Effects 0.000 description 10
- 238000006206 glycosylation reaction Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 9
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 208000003950 B-cell lymphoma Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 206010052015 cytokine release syndrome Diseases 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 6
- 241000235649 Kluyveromyces Species 0.000 description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 201000003444 follicular lymphoma Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 201000005962 mycosis fungoides Diseases 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 206010046766 uterine cancer Diseases 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 5
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 102000048776 human CD274 Human genes 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960003048 vinblastine Drugs 0.000 description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 244000285963 Kluyveromyces fragilis Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 241000256251 Spodoptera frugiperda Species 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229960000640 dactinomycin Drugs 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 102000054751 human RUNX1T1 Human genes 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 210000001370 mediastinum Anatomy 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000255601 Drosophila melanogaster Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 241001524679 Escherichia virus M13 Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 241000311088 Schwanniomyces Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 229910052747 lanthanoid Inorganic materials 0.000 description 3
- 150000002602 lanthanoids Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010073358 Anal squamous cell carcinoma Diseases 0.000 description 2
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 241000221961 Neurospora crassa Species 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 201000005746 Pituitary adenoma Diseases 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 2
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 201000007980 brain meningioma Diseases 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 208000006359 hepatoblastoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000006391 kidney rhabdoid cancer Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000000516 mast-cell leukemia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 201000004058 mixed glioma Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 208000013860 rhabdoid tumor of the kidney Diseases 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- AGAYQLZJBWFZQV-UHFFFAOYSA-N 3-acetyloxolane-2,5-dione Chemical compound CC(=O)C1CC(=O)OC1=O AGAYQLZJBWFZQV-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GBSWEJRAVNWKCB-UHFFFAOYSA-N C12=C(N=C(N=C2)N2CCNCC2)C(NC2=CC(=C(C=C2)OC2=CC=C3C(=C2)N=CN3C)C)=NC=N1 Chemical compound C12=C(N=C(N=C2)N2CCNCC2)C(NC2=CC(=C(C=C2)OC2=CC=C3C(=C2)N=CN3C)C)=NC=N1 GBSWEJRAVNWKCB-UHFFFAOYSA-N 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710128063 Carbohydrate oxidase Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100040835 Claudin-18 Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000749329 Homo sapiens Claudin-18 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000666234 Homo sapiens Thyroid adenoma-associated protein Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930190887 Leptomycin Natural products 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000533524 Powelliphanta augusta Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101150036449 SIRPA gene Proteins 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 102100038148 Thyroid adenoma-associated protein Human genes 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- UQVNRKBFAXNOGA-IUODEOHRSA-N Tomaymycin Natural products CO[C@H]1Nc2cc(O)c(OC)cc2C(=O)N3CC(=CC)C[C@H]13 UQVNRKBFAXNOGA-IUODEOHRSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000005414 dithiopyridyl group Chemical group 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical group 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical class C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
The present disclosure provides novel anti-drug antibodies (in particular, anti-PD-L1/4-1 BB bispecific antibodies), isolated polynucleotides encoding the same, compositions comprising the same, and uses thereof.
Description
Technical Field
The present disclosure relates generally to novel anti-drug antibodies (in particular, anti-drug antibodies to PD-L1/4-1BB bispecific antibodies), antigen-binding fragments thereof, and uses thereof.
Background
Anti-drug antibodies (ADA) are commonly used to detect and quantify therapeutic antibodies during the drug development process. For example, ADA can be used in pharmacokinetic or immunogenicity assays for therapeutic antibodies. In addition, ADA can also be used as a Neutralizing Antibody (NAB) to neutralize the activity of therapeutic antibodies, thereby reducing side effects (e.g., cytokine storms) caused by therapeutic antibodies.
ATG-101 is a PD-L1/4-1BB bispecific antibody designed to activate 4-1BB positive T cells in a manner dependent on PD-L1 cross-linking and to effectively treat tumors without off-target hepatotoxicity (on-target-off-tumor liver toxicity) (see Hui Yuwen et al, J.cancer immunotherapy (J Immunother Cancer) 2021;9 (Prop 2): A1-A1054). In preclinical and clinical studies of ATG-101, molecules capable of recognizing and binding ATG-101 with high affinity are required to detect ATG-101 and thus study PK/PD characteristics of ATG-101.
There remains a need for novel anti-drug antibodies (in particular, anti-drug antibodies to PD-L1/4-1BB bispecific antibodies).
Disclosure of Invention
Throughout this disclosure, the articles "a," "an," and "the" are used herein to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. For example, "an antibody" means one antibody or more than one antibody.
In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof comprising:
one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20, 27, 34, 41, 48 and 55; and/or
One or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.7, 14, 21, 28, 35, 42, 49 and 56.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises at least one heavy or light chain Complementarity Determining Region (CDR) comprising an amino acid sequence selected from the group consisting of: 1, 2, 3, 4, NAK, 5, 8, 9, 10, 11, RAN, 12, 15, 16, 17, 18, AAS, 19, 22, 23, 24, 25, AAS, 26, 29, 30, 31, 32, STS, 33, 36, 37, 38, 39, NAK, 40, 43, 44, 45, 46, NAK, 47, 50, 51, 52, 53, QMS and 54.
In some embodiments, an antibody or antigen-binding fragment thereof of the present disclosure comprises a VH region comprising one or two or three of HCDR1, HCDR2, and HCDR3, the HCDR1, HCDR2, and HCDR3 comprising an amino acid sequence selected from the group consisting of: 1, 2, 3, 8, 9, 10, 15, 16, 17, 22, 23, 24, 29, 30, 31, 36, 37, 38, 43, 44, 45, 50, 51 and 52.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises a VL region comprising one or two or three of LCDR1, LCDR2, and LCDR3, the LCDR1, LCDR2, and LCDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 4, NAK, 5, 11, RAN, 12, 18, AAS, 19, 25, AAS, 26, 32, STS, 33, 39, NAK, 40, 46, NAK, 47, 53, QMS and 54.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
HCDR1, said HCDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 1, 8, 15, 22, 29, 36, 43 and 50;
HCDR2, said HCDR2 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 2, 9, 16, 23, 30, 37, 44 and 51; and
HCDR3, said HCDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 3, 10, 17, 24, 31, 38, 45 and 52.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
LCDR1, said LCDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS 4, 11, 18, 25, 32, 39, 46 and 53;
LCDR2, said LCDR2 comprising an amino acid sequence selected from the group consisting of: NAK, RAN, AAS, AAS, STS, NAK, NAK and QMS; and
LCDR3, said LCDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS 5, 12, 19, 26, 33, 40, 47 and 54.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 1, said HCDR2 comprising an amino acid sequence of SEQ ID No. 2, said HCDR3 comprising an amino acid sequence of SEQ ID No. 3;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 8, said HCDR2 comprising an amino acid sequence of SEQ ID No. 9, said HCDR3 comprising an amino acid sequence of SEQ ID No. 10;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 15, said HCDR2 comprising an amino acid sequence of SEQ ID No. 16, said HCDR3 comprising an amino acid sequence of SEQ ID No. 17;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 22, said HCDR2 comprising an amino acid sequence of SEQ ID No. 23, said HCDR3 comprising an amino acid sequence of SEQ ID No. 24;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 29, said HCDR2 comprising an amino acid sequence of SEQ ID No. 30, said HCDR3 comprising an amino acid sequence of SEQ ID No. 31;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 36, said HCDR2 comprising an amino acid sequence of SEQ ID No. 37, said HCDR3 comprising an amino acid sequence of SEQ ID No. 38;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 43, said HCDR2 comprising an amino acid sequence of SEQ ID No. 44, and said HCDR3 comprising an amino acid sequence of SEQ ID No. 45; or (b)
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 50, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 51 and said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 52.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence as shown in SEQ ID NO. 4, LCDR2 comprises an amino acid sequence as shown in NAK, and LCDR3 comprises an amino acid sequence as shown in SEQ ID NO. 5;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO. 11, LCDR2 comprises the amino acid sequence shown in RAN, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO. 12;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown as SEQ ID NO. 18, LCDR2 comprises the amino acid sequence shown as AAS, and LCDR3 comprises the amino acid sequence shown as SEQ ID NO. 19;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO. 25, LCDR2 comprises the amino acid sequence shown in AAS, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO. 26;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 32, said LCDR2 comprising an amino acid sequence shown as STS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 33;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, and said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 47; or (b)
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO:53, said LCDR2 comprising the amino acid sequence shown as QMS and said LCDR3 comprising the amino acid sequence shown as SEQ ID NO: 54.
In some embodiments, the antibodies of the present disclosure, or antigen-binding fragments thereof, comprise HCDR1, HCDR2 and HCDR3, and LCDR1, LCDR2 and LCDR3, comprised within a VH/VL amino acid sequence pair selected from the group consisting of: SEQ ID NOS 6 and 7, 13 and 14, 20 and 21, 27 and 28, 34 and 35, 41 and 42, 48 and 49, and 55 and 56.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 1, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 2, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 4, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 5;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 12;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 15, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 16, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 17, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 18, said LCDR2 comprising an amino acid sequence shown as AAS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 19;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 22, said HCDR2 comprising an amino acid sequence of SEQ ID No. 23, said HCDR3 comprising an amino acid sequence of SEQ ID No. 24, said LCDR1 comprising an amino acid sequence of SEQ ID No. 25, said LCDR2 comprising an amino acid sequence of AAS, said LCDR3 comprising an amino acid sequence of SEQ ID No. 26;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 36, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 37, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 38, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 43, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 44, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 45, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 47; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 54.
In some embodiments, an antibody or antigen-binding fragment thereof of the present disclosure comprises a VH region having an amino acid sequence as set forth in SEQ ID NOs 6, 13, 20, 27, 34, 41, 48, and 55 or a homologous sequence having at least 80% sequence identity to SEQ ID NOs 6, 13, 20, 27, 34, 41, 48, and 55.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises a VL region having an amino acid sequence as set forth in SEQ ID NOs 7, 14, 21, 28, 35, 42, 49 and 56 or a homologous sequence having at least 80% sequence identity to SEQ ID NOs 7, 14, 21, 28, 35, 42, 49 and 56.
In some embodiments, an antibody or antigen-binding fragment thereof of the present disclosure comprises a VH/VL amino acid sequence pair selected from the group consisting of: SEQ ID NOS 6 and 7, 13 and 14, 20 and 21, 27 and 28, 34 and 35, 41 and 42, 48 and 49, and 55 and 56.
In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, further comprise one or more amino acid residue substitutions or modifications, but still retain specific binding affinity for ATG-101. In some embodiments, at least one of the substitutions or modifications is in one or more CDR sequences of the VH region or the VL region. In some embodiments, at least one of the substitutions or modifications is in one or more non-CDR sequences of the VH region or the VL region. In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, further comprise one or more unnatural amino acid (NNAA) substitutions. In some embodiments, the NNAA is capable of being conjugated.
In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, are capable of specifically binding to the PD-L1 binding portion and/or 4-1BB binding portion of ATG-101, as measured by an ELISA assay. In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure competes with ATG-101 for binding to PD-L1 and/or 4-1BB.
In another aspect, the present disclosure provides an antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment as described above for binding to ATG-101.
In some embodiments, the antibodies of the present disclosure or antigen-binding fragments thereof are chimeric, humanized, or human antibodies or antigen-binding fragments thereof.
In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, are labeled antibodies, bivalent antibodies, anti-idiotype antibodies, or fusion proteins.
In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, are bifunctional antibodies (diabodies), fab ', F (ab') 2 Fd, fv fragment, disulfide stabilized Fv fragment (dsFv), (dsFv) 2 Bispecific dsFv (dsFv-dsFv'), disulfide stabilized bifunctional antibodies (ds diabodies), single chain antibody molecules (scFv), scFv dimers (bivalent diabodies), camelized single domain antibodies, nanobodies, domain antibodies or bivalent domain antibodies.
In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, further comprise an Fc region. In some embodiments, the Fc region is that of a human immunoglobulin (Ig). In some embodiments, the Fc region is that of a human IgG. In some embodiments, the Fc region is derived from human IgG1, igG2, igG3, or IgG4. In some embodiments, the Fc region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS 75-78.
In some embodiments, the light chain of an antibody or antigen binding fragment thereof of the disclosure is a lambda light chain or a kappa light chain.
In some embodiments, the antibodies of the present disclosure, or antigen-binding fragments thereof, are bispecific or multispecific antibodies, or antigen-binding fragments thereof. In some embodiments, the antibodies of the present disclosure, or antigen binding fragments thereof, are capable of specifically binding to the PD-L1 binding portion and the 4-1BB binding portion of ATG-101.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
i. one or two or three of heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20 and 27;
One or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: 34, 41, 48 and 55;
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS 7, 14, 21 and 28; and
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.35, 42, 49 and 56.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 1, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 2, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 4, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 5, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:1, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:2, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:4, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:5, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:36, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:37, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:38, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:39, said LCDR2 comprising an amino acid sequence as shown in NAK, and said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:1, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:2, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:4, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:5, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:43, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:44, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:45, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 47;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:1, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:2, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:4, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:5, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 54;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:12, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:12, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:36, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:37, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:38, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:39, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:12, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:43, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:44, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:45, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 47;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:12, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 54;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:15, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:16, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:17, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:18, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:19, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:15, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:16, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:17, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:18, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:19, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:36, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:37, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:38, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:39, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:15, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:16, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:17, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:18, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:19, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:43, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:44, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:45, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 47;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:15, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:16, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:17, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:18, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO:19, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO:50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO:51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO:52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 54;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 22, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 23, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 24, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 25, said LCDR2 comprising the amino acid sequence shown as AAS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 26, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 29, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 30, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 31, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 32, said LCDR2 comprising the amino acid sequence shown as STS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 22, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 23, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 24, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 25, said LCDR2 comprising the amino acid sequence shown as AAS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 26, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 36, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 37, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 38, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 39, said LCDR2 comprising the amino acid sequence shown as NAK, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 22, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 23, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 24, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 25, said LCDR2 comprising the amino acid sequence shown as AAS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 26, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 43, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 44, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 45, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 46, said LCDR2 comprising the amino acid sequence shown as NAK, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 47; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 22, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 23, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 24, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 25, said LCDR2 comprising the amino acid sequence shown as AAS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 26, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 50, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 51, said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 52, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 53, said LCDR2 comprising the amino acid sequence shown as QMS, said LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 54.
In some embodiments, an antibody or antigen binding fragment thereof of the present disclosure is linked to one or more conjugate moieties. In some embodiments, the conjugate moiety comprises a clearance modifier, a chemotherapeutic agent, a toxin, a radioisotope, a lanthanide, a detectable label (e.g., luminescent label, fluorescent label, enzyme substrate label), a DNA alkylating agent, a topoisomerase inhibitor, a tubulin binding agent, a purification moiety, or other anticancer drug. In some embodiments, the conjugate moiety is covalently linked directly or through a linker.
In another aspect, the present disclosure provides a composition comprising an antibody or antigen-binding fragment thereof of the present disclosure and one or more carriers.
In another aspect, the present disclosure provides a chimeric antigen receptor comprising an antibody or antigen binding fragment thereof of the present disclosure, a transmembrane region, and an intracellular signaling region. In some embodiments, the transmembrane region comprises a transmembrane region of CD3, CD4, CD8 or CD 28. In some embodiments, the intracellular signaling region is selected from the group consisting of: an intracellular signal region sequence of CD3, fccRI, CD27, CD28, CD137, CD134, myD88, CD40, CD278, TLR, or a combination thereof. In some embodiments, the antigen binding fragment of the chimeric antigen receptor is an scFv.
In another aspect, the present disclosure provides a chimeric antigen receptor, wherein the chimeric antigen receptor is transplanted into an allogeneic, autologous or xenogeneic cell.
In another aspect, the present disclosure provides a chimeric antigen receptor, wherein the chimeric antigen receptor is transplanted into an immune effector cell.
In another aspect, the present disclosure provides a chimeric antigen receptor, wherein the chimeric antigen receptor is transplanted into a T cell, a natural killer cell, a macrophage, or a tumor-infiltrating lymphocyte.
In another aspect, the present disclosure provides a composition comprising an antibody or antigen-binding fragment thereof or chimeric antigen receptor of the present application, and one or more carriers.
In another aspect, the present disclosure provides an isolated polynucleotide encoding an antibody or antigen binding fragment thereof of the present disclosure and/or a chimeric antigen receptor of the present disclosure.
In another aspect, the present disclosure provides a vector comprising an isolated polynucleotide of the present disclosure.
In another aspect, the present disclosure provides a host expression system comprising a vector of the present disclosure or a polynucleotide of the present disclosure having integrated into its genome. In some embodiments, the host expression system of the present disclosure is a microorganism, a yeast, or a mammalian cell, wherein the microorganism is selected from the group consisting of escherichia coli (e.coli) and bacillus subtilis (b.subtilis), optionally wherein the yeast is Saccharomyces (Saccharomyces), and optionally wherein the mammalian cell is selected from the group consisting of: COS, CHO-S, CHO-K1, HEK-293 and 3T3 cells.
In another aspect, the present disclosure provides a virus comprising a vector of the present disclosure.
In another aspect, the present disclosure provides a method of expressing an antibody or antigen-binding fragment thereof or chimeric antigen receptor of the present disclosure, the method comprising culturing a host expression system of the present disclosure under conditions that express the antibody or antigen-binding fragment thereof or chimeric antigen receptor of the present disclosure.
In another aspect, the present disclosure provides a method of detecting the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in a sample, the method comprising contacting the sample with an antibody or antigen-binding fragment thereof of the present disclosure and/or a composition of the present disclosure and/or a chimeric antigen receptor of the present disclosure and determining the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in the sample. In some embodiments, the method is a non-diagnostic method. In some embodiments, the method is a diagnostic method. In some embodiments, the methods are used in pharmacokinetic, drug resistance or neutralization assays for anti-PD-L1 antibodies, anti-4-1 BB antibodies, or bispecific PD-L1/4-1BB antibodies. In some embodiments, the method is used in a pharmacokinetic, drug resistance or neutralization assay for ATG-101.
In another aspect, the present disclosure provides a method of reducing side effects caused by administration of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody to a subject, the method comprising administering to the subject an antibody of the present disclosure or an antigen-binding fragment thereof and/or a composition of the present disclosure and/or a chimeric antigen receptor of the present disclosure. In some embodiments, the side effect is a cytokine storm. In some embodiments, the anti-PD-L1 antibody, the anti-4-1 BB antibody, or the bispecific PD-L1/4-1BB antibody is administered to the subject to prevent or treat a disease, disorder, or condition associated with PD-L1 and/or 4-1 BB.
In some embodiments, the disease, disorder, or condition associated with PD-L1 and/or 4-1BB is cancer. In some embodiments, the cancer is a solid tumor or a hematological tumor. In some embodiments, the disease, disorder, or condition associated with PD-L1 and/or 4-1BB is selected from the group consisting of: lung cancer (e.g., non-small cell lung cancer (NSCLC), small Cell Lung Cancer (SCLC) (lung adenocarcinoma or lung squamous cell carcinoma), peritoneal cancer, carcinoid, bone cancer, pancreatic cancer, primitive neuroectodermal tumors, skin cancer, gall bladder cancer, head and neck cancer, squamous cell cancer, uterine cancer, ovarian cancer, rectal cancer, prostate cancer, bladder cancer (e.g., urothelial cancer), anal region cancer (e.g., anal squamous cell cancer), gastric cancer (gastric or stomach cancer) (e.g., gastrointestinal cancer), esophageal cancer, colon cancer, breast cancer, uterine cancer, liver cancer (e.g., hepatoblastoma, hepatocellular carcinoma/hepatoma or liver cancer), cholangiocarcinoma, sarcoma, colorectal cancer, fallopian tube cancer, salivary gland cancer, cervical cancer, endometrial or uterine cancer, osteosarcoma, vaginal cancer, vulval cancer, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, nasopharyngeal cancer, soft tissue sarcoma, polycythemia vera, real world cancer, penile cancer, kidney or urinary tract cancer (e.g., renal rhabdoid tumor), cutaneous T cell lymphoma, medulloblastoma, nephroblastoma, myelodysplastic syndrome, chronic and non-chronic myeloproliferative disorders, chorioallantoic papilloma, renal cell carcinoma, renal pelvis carcinoma, central Nervous System (CNS) neoplasm, soft tissue sarcoma (e.g., rhabdomyosarcoma, fibrosarcoma, kaposi's sarcoma), spinal cord shaft tumor, glioma (e.g., ependymoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma), eye cancer (e.g., retinoblastoma), brain stem glioma or mixed glioma such as oligodendroastrocytoma, brain tumor (e.g., glioblastoma/glioblastoma multiforme (GBM), non-glioblastoma brain tumor or meningioma), cutaneous or intraocular melanoma, thrombocythemia, mesothelioma, mycosis fungoides, sezary syndrome (Sezary syndrome), primary myelofibrosis, isolated plasmacytomer, vestibular schwannoma, ewing's sarcoma, chondrosarcoma, MYH-related polyposis, pituitary adenoma, pediatric cancers such as pediatric sarcomas (e.g., neuroblastoma, rhabdomyosarcoma and osteosarcoma), hematologic cancers, hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia (e.g., lymphoblastic/lymphoblastic leukemia), chronic or acute leukemia, mast cell leukemia, lymphocytic lymphoma, primary CNS lymphoma, chronic Lymphocytic Leukemia (CLL), acute Lymphoblastic Leukemia (ALL), chronic Myelogenous Leukemia (CML), acute Myelogenous Leukemia (AML), chronic myelomonocytic leukemia (CMML), chronic lymphocytic leukemia, acute lymphoblastic leukemia, hairy Cell Leukemia (HCL), burkitt's Lymphoma (BL), multiple myeloma (e.g., recurrent or refractory multiple myeloma), T-cell or B-cell lymphoma, mantle Cell Lymphoma (MCL) (e.g., recurrent or refractory mantle cell lymphoma), malignant melanoma, diffuse large B-cell lymphoma (DLBCL), DLBCL caused by follicular lymphoma, advanced B-cell lymphoma, primary mediastinum large B-cell lymphoma, follicular Lymphoma (FL) and primary mediastinum B-cell lymphoma.
In some embodiments, the antibodies of the present disclosure or antigen-binding fragments thereof and/or the compositions of the present disclosure and/or the chimeric antigen receptors of the present disclosure are used to neutralize the anti-PD-L1 antibody, the anti-4-1 BB antibody, or the bispecific PD-L1/4-1BB antibody.
In another aspect, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof of the present disclosure and/or a composition of the present disclosure and/or a chimeric antigen receptor of the present disclosure.
In another aspect, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof of the present disclosure, and/or a chimeric antigen receptor of the present disclosure, and/or a composition of the present disclosure, which can be used to detect an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in a sample.
In another aspect, the present disclosure provides a kit comprising an antibody of the present disclosure, or an antigen-binding fragment thereof, and/or a chimeric antigen receptor of the present disclosure, and/or a composition of the present disclosure, for detecting an anti-drug antibody (ADA) that is an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody.
In another aspect, the present disclosure provides for the use of an antibody or antigen binding fragment thereof provided herein, and/or a chimeric antigen receptor of the disclosure, and/or a composition of the disclosure, in the preparation of a kit for use in a method for detecting an anti-drug antibody (ADA) to a PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody.
In some embodiments, the sample is selected from the group consisting of: tissue sections, biopsies, paraffin embedded tissue, body fluids, colonic exudates, surgical resection samples, isolated blood cells, cells isolated from blood, and any combination thereof.
In some embodiments, an antibody or antigen-binding fragment thereof of the present disclosure includes a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof.
In some embodiments, the first antibody or antigen binding fragment thereof comprises:
i. one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) included within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20 and 27; and
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and LCDR 3) included within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.7, 14, 21 and 28.
In some embodiments, the first antibody or antigen binding fragment thereof comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 1, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 2, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 4, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 5;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 12;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 15, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 16, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 17, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 18, said LCDR2 comprising an amino acid sequence shown as AAS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 19; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 22, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 23, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 24, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 25, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 26.
In some embodiments, the second antibody or antigen binding fragment thereof comprises:
i. one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) included within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: 34, 41, 48 and 55; and
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and LCDR 3) included within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.35, 42, 49 and 56.
In some embodiments, the second antibody or antigen binding fragment thereof comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 36, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 37, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 38, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 43, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 44, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 45, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 46, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 47; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 54.
In some embodiments, the bodily fluid is selected from the group consisting of: whole blood, serum, plasma, urine, mucus, saliva, peritoneal fluid, pleural fluid, synovial fluid, cerebrospinal fluid, pleural effusion, peritoneal effusion, and any combination thereof.
In some embodiments, the bispecific PD-L1/4-1BB antibody is ATG-101.
Drawings
FIGS. 1A through 1F show the binding affinities of antibody clones 10F10G7, 9D6E11, 27E8A8, 31B6G8, 50D6E10, 58H6F8, 63C9C12 and 75H9F7 for ATG-101 and IgG, respectively.
FIGS. 2A to 2C show the binding affinity and competition capacity of selected antibody clones (10F 10G7, 9D6E11, 27E8A8, 31B6G8, 50D6E10, 58H6F8, 63C9C12, 75H9F 7) against ATG-101 for human PD-L1 protein or human 4-1BB protein. Mouse IgG1 was used as a non-competitive negative control.
FIG. 3 shows the structure of ATG-101.
Detailed Description
The following description of the present disclosure is intended only to illustrate various embodiments of the present disclosure. As such, the particular modifications discussed should not be construed as limiting the scope of the present disclosure. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of the disclosure, and it is to be understood that such equivalent embodiments are to be included herein. All documents, including publications, patents and patent applications cited herein are incorporated by reference in their entirety.
Definition of the definition
The term "antibody" as used herein includes any immunoglobulin, monoclonal antibody, polyclonal antibody, multivalent antibody, bivalent antibody, monovalent antibody, multispecific antibody, or bispecific antibody that binds to a particular antigen. Natural intact antibodies comprise two heavy (H) chains and two light (L) chains. Mammalian heavy chains are divided into α, δ, ε, γ and μ, each heavy chain comprising a variable region (VH) and a first constant region, a second constant region, a third constant region and optionally a fourth constant region (CH 1, CH2, CH3, CH4, respectively); mammalian light chains are classified as either lambda or kappa, and each light chain includes a variable region (VL) and a constant region. The antibody is "Y" shaped, wherein the stem of the Y-shaped structure comprises a second constant region and a third constant region of two heavy chains that are joined together by disulfide bonds. Each arm of Y comprises a variable region and a first constant region of a single heavy chain in combination with a variable region and a constant region of a single light chain. The variable regions of the light and heavy chains are responsible for antigen binding. The variable region of each chain typically contains three hypervariable regions, known as Complementarity Determining Regions (CDRs) (light chain CDRs comprising LCDR1, LCDR2, LCDR3, heavy chain CDRs comprising HCDR1, HCDR2, HCDR 3). The three CDRs are separated by flanking regions called Framework Regions (FR) (light chain FR includes LFR1, LFR2, LFR3 and LFR4, and heavy chain FR includes HFR1, HFR2, HFR3 and HFR 4) that are more highly conserved than the CDRs and form scaffolds to support highly variable loops. The constant regions of the heavy and light chains are not involved in antigen binding, but exhibit a variety of effector functions. Antibodies can be classified into several classes based on the amino acid sequence of their heavy chain constant region. The five main classes or isotypes of antibodies are IgA, igD, igE, igG and IgM, which are characterized by the presence of alpha, delta, epsilon, gamma and mu heavy chains, respectively. Several major antibody classes are divided into subclasses, such as IgG1 (gamma 1 heavy chain), igG2 (gamma 2 heavy chain), igG3 (gamma 3 heavy chain), igG4 (gamma 4 heavy chain), igA1 (alpha 1 heavy chain) or IgA2 (alpha 2 heavy chain).
In certain embodiments, the antibodies provided herein encompass any antigen-binding fragment thereof. As used herein, the term "antigen-binding fragment" refers to an antibody fragment formed from a portion of an antibody that includes one or more (e.g., 1, 2, 3, 4, 5, or 6) CDRs, or any other antibody fragment that binds an antigen but does not include the complete native antibody structure. Examples of antigen binding fragments include, but are not limited to, bifunctional antibodies (diabodies), fab ', F (ab') 2 Fd, fv fragment, disulfide stabilized Fv fragment (dsFv), (dsFv) 2 Bispecific dsFv (dsFv-dsFv'), disulfide stabilized bifunctional antibodies (ds diabody), single chain antibody molecules (scFv), scFv dimers (bivalent bifunctional antibodies), bispecific antibodies, multispecific antibodies, camelid single domain antibodies, nanobodies, domain antibodies, or bivalent domain antibodies. The antigen binding fragment is capable of binding the same antigen or epitope as the parent antibody.
"Fab" of an antibody refers to a portion of an antibody consisting of a single light chain (including variable and constant regions) and the variable and first constant regions of a single heavy chain joined by disulfide bonds.
"Fab'" refers to a Fab fragment which comprises a portion of the hinge region.
“F(ab’) 2 "refers to a dimer of Fab'.
"Fc" of an antibody (e.g., an IgG, igA, or IgD isotype) refers to the portion of the antibody that is composed of the second constant domain and the third constant domain of the first heavy chain that binds to the second constant domain and the third constant domain of the second heavy chain via disulfide bonds. The Fc of IgM and IgE isotype antibodies further comprises a fourth constant domain. The Fc portion of antibodies is responsible for a number of different effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), but does not play a role in antigen binding.
"Fv" of an antibody refers to the smallest antibody fragment that contains the complete antigen binding site. Fv fragments consist of a single light chain variable region in combination with a single heavy chain variable region.
"Single chain Fv antibody" or "scFv" refers to an engineered antibody consisting of a light chain variable region and a heavy chain variable region, either directly linked to each other or linked to each other by a linker (e.g., a peptide sequence) (Huston JS et al, proc. Natl. Acad. Sci. USA (Proc Natl Acad Sci USA), 85:5879 (1988)).
"Single chain Fv-Fc antibody" or "scFv-Fc" refers to an engineered antibody consisting of an scFv linked to the Fc region of the antibody.
"camelized single domain antibody", "heavy chain antibody" or "HCAb" refers to an antibody containing two VH domains and no light chain (Riechmann L. And Muyldermans S., "J.Immunol.methods (J Immunol Methods)," 12 months for 10 days; 231 (1-2): 25-38 (1999); muyldermans S., "J.Biotechnol.)," 6 months; 74 (4): 277-302 (2001); WO94/04678; WO94/25591; U.S. Pat. No. 6,005,079). Heavy chain antibodies were originally derived from Camelidae (camel, dromedary and llama). The camelized antibody has a confirmed antigen binding full function despite deletion of the light chain (Hamers-Casterman C. Et al, nature) 6 months 3, 363 (6428) 446-8 (1993), nguyen VK. et al, immunogenetics (Immunogenetics) 4 months, 54 (1) 39-47 (2002), nguyen VK. et al, immunology (Immunology) 5 months, 109 (1) 93-101 (2003)). The variable region (VHH domain) of a heavy chain antibody represents the smallest known antigen binding unit generated by an adaptive immune response (Koch-Nolte F. Et al, journal of the American society of laboratory Biotechnology (FASEB J.)) 11 months; 21 (13): 3490-8 electronic version 2007, 6, 15 (2007)).
"nanobody" refers to an antibody fragment consisting of a VHH domain from a chain antibody and two constant domains CH2 and CH 3.
"diabodies", "diabodies" or "dAbs" include small antibody fragments having two antigen binding sites, wherein the fragments comprise a VH domain and a VL domain (VH-VL or VL-VH) linked on the same polypeptide chain (see, e.g., holliger P. Et al, proc. Natl. Acad. Sci. USA, 7, 15 days; 90 (14): 6444-8 (1993); EP404097; WO 93/11161). By using a linker that is too short to allow pairing between two domains on the same strand, the domains are forced to pair with the complementary domain of the other strand, thereby creating two antigen binding sites. The antigen binding sites may target the same or different antigens (or epitopes). In certain embodiments, a "bispecific ds bifunctional antibody" is a bifunctional antibody that targets two different antigens (or epitopes).
"domain antibody" refers to an antibody fragment containing only heavy chain variable regions or light chain variable regions. In certain cases, two or more VH domains are covalently joined by a peptide linker to produce a bivalent or multivalent domain antibody. The two VH domains of a bivalent domain antibody may target the same or different antigens (or epitopes).
As used herein, the term "valency" refers to the presence of a specified number of antigen binding sites in a given molecule. The term "monovalent" refers to an antibody or antigen binding fragment having only one antigen binding site; and the term "multivalent" refers to an antibody or antigen binding fragment having multiple antigen binding sites. Thus, the terms "divalent", "tetravalent" and "hexavalent" denote the presence of two antigen binding sites, four antigen binding sites and six antigen binding sites, respectively, in an antigen binding molecule. In some embodiments, the antibody or antigen binding fragment thereof is bivalent.
As used herein, a "bispecific" antibody refers to an artificial antibody having fragments derived from two different monoclonal antibodies and capable of binding to two different epitopes. The two epitopes may be present on the same antigen, or they may be present on two different antigens.
As used herein, a "multispecific" antibody refers to an antibody that specifically binds to at least two different antigens or at least two different epitopes of the same antigen. The multispecific antibodies may bind to, for example, two, three, four, five, or more different antigens, or may bind to two, three, four, five, or more different epitopes of the same antigen.
In certain embodiments, the "scFv dimer" is a bivalent bifunctional antibody (diabody) or a bispecific scFv (BsFv) comprising two VH-VL (linked by a peptide linker) portions that dimerize such that the VH of one portion cooperates with the VL of the other portion to form two binding sites that can target the same antigen (or epitope) or different antigens (or epitopes). In other embodiments, a "scFv dimer" is a bispecific bifunctional antibody comprising VH1-VL2 (linked by a peptide linker) and VL1-VH2 (also linked by a peptide linker) that are associated with each other such that VH1 and VL1 cooperate, VH2 and VL2 cooperate, and each cooperating pair has a different antigen specificity.
"dsFv" refers to a disulfide stabilized Fv fragment in which the linkage between the variable region of a single light chain and the variable region of a single heavy chain is disulfide. In some embodiments, "(dsFv) 2 "or" (dsFv-dsFv') "includes three peptide chains: the two VH moieties are linked by a peptide linker (e.g., a long flexible linker) and are bound to the two VL moieties, respectively, by disulfide bonds. In some embodiments, dsFv-dsFv' having dual specificity, wherein each pair of heavy and light chains paired by disulfide bonds has Different antigen specificity.
As used herein, the term "chimeric" refers to an antibody or antigen binding fragment having a portion of the heavy and/or light chain derived from one species and the remainder of the heavy and/or light chain derived from a different species. In an illustrative example, a chimeric antibody can include a constant region derived from a human and a variable region derived from a non-human animal (e.g., a mouse). In some embodiments, the non-human animal is a mammal, such as a mouse, rat, rabbit, goat, sheep, guinea pig, or hamster.
As used herein, the term "humanized" refers to antibodies or antigen binding fragments that comprise CDRs derived from a non-human animal, FR regions derived from a human, and constant regions (when applicable) derived from a human. The CDRs of the humanized antibodies provided by the present disclosure can contain mutations compared to the CDRs of their parent antibodies.
As used herein, the term "affinity" refers to the strength of a non-covalent interaction between an immunoglobulin molecule (i.e., an antibody) or antigen-binding fragment thereof and an antigen.
Antibodies or antigen binding fragments thereof that "specifically bind" (specifically binds/specific binding) to a target (e.g., an epitope) are well known in the art and methods for determining such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" if it reacts or associates more frequently, more rapidly, longer in duration, and/or with greater affinity than it does with a particular cell or substance. An antibody "specifically binds" to a target if it binds more strongly, more readily, and/or for a longer duration than it does with other substances. For example, an antibody that specifically binds to a PD-L1 epitope is an antibody that binds to this PD-L1 epitope with greater affinity, higher affinity, easier and/or longer duration than binds to other PD-L1 epitopes or non-PD-L1 epitopes. It will also be appreciated by reading this definition that, for example, an antibody (or portion or epitope) that specifically binds to a first target may or may not specifically bind to a second target. As such, "specific binding" (specific binding/specifically bind) does not necessarily require (although it may include) exclusive binding. Generally, but not necessarily, reference to binding refers to specific binding.
As used herein, the term "epitope" refers to a specific set of atoms or amino acids on an antigen to which an antibody binds. If both antibodies exhibit competitive binding to an antigen, they may bind to the same or closely related epitope within the antigen. Epitopes can be linear or spatially conformational (i.e., include spaced apart amino acid residues). For example, an antibody or antigen-binding portion may be considered to bind the same or closely related epitope as a reference antibody if the antibody or antigen-binding fragment blocks at least 85%, or at least 90%, or at least 95% of the binding of the reference antibody to the antigen.
As used herein, the term "amino acid" refers to a polypeptide containing an amino group (-NH) 2 ) And a carboxyl (-COOH) functional group, and a side chain unique to each amino acid. Amino acid names are also indicated in the present disclosure in standard single-letter or three-letter codes, summarized below:
"conservative substitution" with respect to an amino acid sequence refers to the replacement of an amino acid residue with a different amino acid residue having a side chain of similar physicochemical properties. For example, conservative substitutions may be made between amino acid residues having a hydrophobic side chain (e.g., met, ala, val, leu and Ile), amino acid residues having a neutral hydrophilic side chain (e.g., cys, ser, thr, asn and gin), amino acid residues having an acidic side chain (e.g., asp, glu), amino acid residues having a basic side chain (e.g., his, lys, and Arg), or amino acid residues having an aromatic side chain (e.g., trp, tyr, and Phe). As is known in the art, conservative substitutions typically do not cause a significant change in the conformational structure of the protein, and thus may preserve the biological activity of the protein.
As used herein, the term "homologous" refers to a nucleic acid sequence (or its complementary strand) or amino acid sequence that has at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to another sequence when optimally aligned.
"percent (%) sequence identity" with respect to an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to amino acid (or nucleic acid) residues in a reference sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum number of identical amino acids (or nucleic acids). In other words, the percent (%) sequence identity of an amino acid sequence (or nucleic acid sequence) can be calculated by dividing the number of identical amino acid residues (or bases) relative to the reference sequence to which it is compared by the total number of amino acid residues (or bases) in the candidate sequence or reference sequence (whichever is shorter). Conservative substitutions of amino acid residues may or may not be considered as identical residues. The alignment can be accomplished, for example, using publicly available tools such as BLASTN, BLASTp (available on the website of the national institute of biological technology (U.S. national Center for Biotechnology Information, NCBI), see also Altschul S.F. et al, (J. Mol. Biol.), 215:403-410 (1990), stephen F. Et al, (Nucleic Acids Res.), 25:3389-3402 (1997)), clustalW2 (available on the website of the European institute of biological information (European Bioinformatics Institute), see also Higgins D.G. et al, methods of enzymology (Methods In Enzymology), 266:383-402 (1996), larkin M.A. et al, (Bioinformatics) (British oxford.), 23 (21) 2947-8 (2007) or Megalign (DNASTAR) software to determine the identity of amino acid sequences, or Nucleic acid sequences, and the appropriate parameters can be selected by a person in accordance with the appropriate algorithm of the art, for example, by appropriate choice of the appropriate parameters.
As used herein, "effector function" refers to biological activity caused by the binding of an Fc region of an antibody to its effectors (e.g., C1 complex and Fc receptor). Exemplary effector functions include: complement Dependent Cytotoxicity (CDC) mediated by the interaction of the antibody with C1q on the C1 complex; antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by binding of the Fc region of an antibody to an Fc receptor on an effector cell; phagocytosis. Various assays, such as Fc receptor binding assays, C1q binding assays, and cell lysis assays, can be used to assess effector function.
As used herein, "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a cell-mediated reaction in which effector cells expressing an Fc receptor (FcR) recognize a binding antibody or antigen binding fragment on a target cell and subsequently cause lysis of the target cell. "ADCC activity" or "ADCC effect" refers to the ability of an antibody or antigen binding fragment bound to a target cell to initiate an ADCC reaction as described above.
As used herein, "complement dependent cytotoxicity" or "CDC" refers to a mechanism by which an antibody can mediate specific target cell lysis by activating the complement system of an organism. In CDC, C1q binds to antibodies and this binding triggers the complement cascade, which results in the formation of a Membrane Attack Complex (MAC) at the target cell surface (C5 b to C9) as a result of classical pathway complement activation. "CDC activity" or "CDC effect" refers to the ability of an antibody or antigen binding fragment to bind to a target cell to elicit a CDC reaction as described above.
As used herein, "target cell" refers to a cell that includes an Fc region to which an antibody specifically binds. An "effector cell" is a leukocyte that expresses one or more Fc receptors and performs effector functions. Examples of human leukocytes that mediate ADCC include Peripheral Blood Mononuclear Cells (PBMC), natural Killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils; of these, PBMC and NK cells are preferred. Effector cells may be isolated from their natural sources, for example from blood or PBMCs as known in the art.
"isolated" substances have been altered manually by natural states. If a certain "isolated" composition or substance occurs in nature, it has been altered or removed from its original environment, or both. For example, a polynucleotide or polypeptide naturally occurring in a living animal is not "isolated," but may be considered "isolated" if the polynucleotide or polypeptide is sufficiently separated from the material in which it coexists in its natural state and exists in a substantially pure state. An "isolated nucleic acid sequence" refers to the sequence of an isolated nucleic acid molecule. In certain embodiments, an "isolated antibody or antigen-binding fragment thereof" refers to an antibody or antigen-binding fragment thereof that is at least 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure, as determined by an electrophoretic method (e.g., SDS-PAGE, isoelectric focusing, capillary electrophoresis) or a chromatographic method (e.g., ion exchange chromatography or reverse phase HPLC).
As used herein, the term "vector" refers to a vector into which a polynucleotide encoding a protein may be operably inserted so as to cause expression of the protein. Vectors may be used to transform, transduce or transfect host cells such that the genetic elements carried thereby are expressed within the host cells. Examples of vectors include plasmids, phagemids, cosmids, artificial chromosomes such as Yeast Artificial Chromosomes (YACs), bacterial Artificial Chromosomes (BACs) or P1-derived artificial chromosomes (PACs), phages such as lambda phages or M13 phages, and animal viruses. Classes of animal viruses used as vectors include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, and papovaviruses (e.g., SV 40). The vector may contain a variety of elements for controlling expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selectable elements, and reporter genes. In addition, the vector may contain an origin of replication. The carrier may also include materials that assist in its entry into the cell, including but not limited to viral particles, liposomes, or protein coatings. The vector may be an expression vector or a cloning vector. The present disclosure provides vectors (e.g., expression vectors) comprising a nucleic acid sequence provided herein encoding an antibody or antigen binding fragment thereof, at least one promoter (e.g., SV40, CMV, EF-1 a) operably linked to the nucleic acid sequence, and at least one selectable marker. Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papovaviruses (e.g., SV 40), lambda and M13 phages, plasmids pcDNA3.3, pMD18-T, pOptivec, pCMV, pEGFP, pIRES, pQD-Hyg-Gseu, pALTER, pBAD, pcDNA, pCal, pL, pET, pGEMEX, pGEX, pCI, pEGFT, pSV2, pFUSE, pVITRO, pVIVO, pMAL, pMONO, pSELECT, pUNO, pDUO, psg5L, pBABE, pWPXL, pBI, p15TV-L, pPro18, pTD, pRS10, pLexA, pACT2.2, pCMV-SCRIPT.RTM, pCDM8, pCDNA1.1/amp, pcDNA3.1, pRc/RSV, PCR 2.1, pEF-1, pFB, pSG5, pXT1, pCDEF3, pSVSPORT, pEF-Bos, and the like.
As used herein, the phrase "host cell" refers to a cell into which an exogenous polynucleotide and/or vector may or has been introduced.
The term "subject" includes both human and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, mice, rats, cats, rabbits, sheep, dogs, cattle, chickens, amphibians, and reptiles. The terms "patient," "subject," or "individual" are used interchangeably herein, except where indicated.
The term "anti-tumor activity" means a decrease in proliferation, viability or metastatic activity of tumor cells. For example, anti-tumor activity may be indicated by a decrease in the growth rate of abnormal cells or a decrease in tumor size stability or a decrease in survival due to treatment or due to treatment, as compared to a control without treatment. Such activity may be assessed using accepted in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, mouse Mammary Tumor Virus (MMTV) models, and other known models known in the art to study anti-tumor activity.
As used herein, "treating" or "treatment" of a disease, disorder or condition includes preventing or alleviating the disease, disorder or condition, slowing the onset or rate of progression of the disease, disorder or condition, reducing the risk of developing the disease, disorder or condition, preventing or slowing the progression of symptoms associated with the disease, disorder or condition, reducing or ending symptoms associated with the disease, disorder or condition, causing complete or partial regression of the disease, disorder or condition, curing the disease, disorder or condition, or some combination thereof.
As used herein, the term "biological sample" or "sample" refers to a biological composition obtained from or derived from a subject of interest that contains cells and/or other molecular entities to be characterized and/or identified, e.g., based on physical, biochemical, chemical, and/or physiological characteristics. Biological samples include, but are not limited to, cells, tissues, organs and/or biological fluids of a subject obtained by any method known to those of skill in the art. In some embodiments, the biological sample is a body fluid sample. In some embodiments, the bodily fluid sample is whole blood, plasma, serum, mucus (including nasal drainage and sputum), peritoneal fluid, pleural fluid, thoracic fluid, saliva, urine, synovial fluid, cerebrospinal fluid (CSF), thoracic fluid, peritoneal fluid, ascites, or pericardial fluid. In some embodiments, the biological sample is a tissue or cell obtained from the stomach, heart, liver, spleen, lung, kidney, skin, or blood vessel of the subject.
As used herein, "PD-L1", also referred to as B7-H1 or CD274, refers to the programmed cell death ligand 1 (PD-L1, see, e.g., freeman et al (2000), "journal of experimental medicine (j.exp. Med.))," 192:1027) protein, and includes any variant, conformation, isoform and species homolog of PD-L1 that is expressed by cells naturally or by cells transfected with the PD-L1 gene. For example, PD-L1 described herein may refer to PD-L1 proteins derived from any vertebrate source, including mammals such as primates (e.g., humans, monkeys) and rodents (e.g., mice and rats). It is expressed in placenta, spleen, lymph node, thymus, heart, fetal liver, and can also be found on many tumor cells or cancer cells. NCBI accession number: NP 054862.1 (representative amino acid sequence) and NCBI accession numbers: exemplary sequences of human PD-L1 are disclosed in NM-014143.3 (representative nucleic acid sequences). Exemplary sequences of non-human PD-L1 include: cynomolgus monkey (Macaca fascicularis) (monkey) PD-L1 protein (NCBI Ref Seq No. xm_ 005581779.3); mice (Mus musculus) (mice) PD-L1 protein (NCBI Ref Seq No. adk 70950.1); brown mice (Rattus norvegicus) (rats) PD-L1 protein (NCBI Ref Seq No. NP-001178883.1). In certain embodiments, PD-L1 as used herein may also be recombinant PD-L1, which recombinant PD-L1 may optionally be expressed in the form of a recombinant PD-L1 complex. The recombinant PD-L1 complex may be expressed on the cell surface or may be expressed in a soluble form that does not bind to the cell surface. In certain embodiments, PD-L1 is human PD-L1. The terms "PD-L1", "PDL1", "B7H1", "B7-H1" and "CD274" are used interchangeably in this disclosure.
As used herein, the term "4-1BB", also known as CD137 or tumor necrosis factor receptor superfamily member 9 (TNFRSF 9), refers to the 4-1BB protein and includes any variant, conformation, isoform and species homolog of 4-1BB expressed naturally by cells or expressed by cells transfected with the 4-1BB gene. For example, 4-1BB as described herein may refer to 4-1BB protein derived from any vertebrate source, including mammals such as primates (e.g., humans, monkeys) and rodents (e.g., mice and rats). Exemplary sequences of human 4-1BB are disclosed in NCBI accession numbers NP-001552.2, NM-001561.5, XP-011539688.1, or XM-011541386.2. Exemplary sequences for non-human 4-1BB include: cynomolgus monkey (monkey) 4-1BB protein (NCBI Ref Seq No. ABY 47575.1); the mouse (mouse) 4-1BB protein (NCBI Ref Seq No. NP-001070977.1 NM_001077509.1, NP_035742.1, NM_011612.2, XP_011248530.1, XM_ 011250228.2); brown rat (rat) 4-1BB protein (NCBI Ref Seq No. NP-852049.1, NP-001020944.1, AAH 97483.1). In certain embodiments, 4-1BB as used herein may also be recombinant 4-1BB, which recombinant 4-1BB may optionally be expressed in the form of a recombinant PD-L1 complex. The recombinant 4-1BB complex may be expressed on the cell surface, or may be expressed in a soluble form that does not bind to the cell surface. In certain embodiments, 4-1BB is human 4-1BB. The terms "4-1BB", "41BB", "CD137", "CD-137", "CD137" and "TNFRSF9" may be used interchangeably throughout this disclosure.
As used herein, "a disease, disorder, or condition associated with PD-L1 and/or 4-1 BB" or "a disease, disorder, or condition associated with PD-L1 and/or 4-1 BB" refers to any disease, disorder, or condition caused by, exacerbated by, or otherwise linked to an increase or decrease in the expression or activity of PD-L1 and/or 4-1 BB. In some embodiments, the disease, disorder, or condition associated with PD-L1 and/or 4-1BB is a disorder associated with excessive cell proliferation, such as cancer. In certain embodiments, the disease, disorder, or condition is characterized by expression or overexpression of PD-L1 and/or 4-1BB or a gene associated with PD-L1 and/or 4-1 BB.
Antibodies to
In one aspect, the disclosure provides antibodies and antigen binding fragments thereof that specifically bind to an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody. In some embodiments, the present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to ATG-101.
As used herein, the term "ATG-101" is a homodimeric bifunctional molecule targeting PD-L1 and 4-1BB, comprising a fully human IgG1 antibody to PD-L1 and an scFv to 4-1BB, wherein the scFv to 4-1BB comprises a VH region to 4-1BB and a VL region to 4-1BB, and the VH regions are linked by a linker (e.g., (GGGGS) 3 ) Is linked to the VL region and the VH region of the scFv is via a linker (e.g., (GGGGS) 3 ) Is linked to the C-terminus of the Fc region of a fully human IgG1 antibody directed against PD-L1. In some embodiments, the asparagine at position 297 of ATG-101 (according to the EP numbering system) is mutated to alanine to eliminate binding affinity for the Fcγ receptor. Throughout this specification, the fully human IgG1 antibody to PD-L1 of ATG-101 is referred to as the "PD-L1 binding portion" of ATG-101, and the scFv of ATG-101 to 4-1BB is referred to as the "4-1BB binding portion" of ATG-101. The amino acid sequences of the HCDR, LCDR, VH region, the VL region, the heavy chain and the light chain of ATG-101 are shown in Table 1. The CDR boundaries of ATG-101 in Table 1 are determined according to the IMGT rules.
TABLE 1 amino acid sequences of the HCDR, LCDR, VH region, VL region, heavy chain and light chain of ATG-101
/>
The binding affinity of an antibody or antigen binding fragment thereof provided herein may be determined by K D The value represents the ratio (k) of the dissociation rate to the association rate when the binding between antigen and antigen binding molecule reaches equilibrium off /k on ). Antigen binding affinity (e.g., K) can be suitably determined using suitable methods known in the art, including, for example, flow cytometry assays D ). In some embodiments, binding of an antibody or antigen binding fragment thereof to different concentrations of antigen can be determined by flow cytometry, the determined Mean Fluorescence Intensity (MFI) can be first plotted against the antibody concentration, and K can be calculated by fitting the dependence of the specific binding fluorescence intensity (Y) and antibody concentration (X) to one site saturation equation (site saturation equation) using Prism version 5 (San Diego, california) GraphPad software (GraphPad Software, san Diego, CA)) D Value: y=b max *X/(K D +X), wherein B max Refers to the maximum specific binding of the antibody to be tested to the antigen.
The binding of the antibodies or antigen binding fragments thereof provided herein to ATG-101 may also be performed using "half maximal effective concentrations" (EC 50 ) The values represent the maximum observed for the antibodiesConcentration of 50% of binding. EC (EC) 50 The value may be measured by binding assays known in the art, such as direct or indirect binding assays, e.g., enzyme-linked immunosorbent assays (ELISA), FACS assays, and other binding assays. In certain embodiments, an antibody or antigen binding fragment thereof provided herein is capable of specifically binding to ATG-101 (e.g., as measured by an ELISA assay). In certain embodiments, an antibody or antigen binding fragment thereof provided herein is capable of specifically binding to a PD-L1 binding portion of ATG-101 (e.g., as measured by an ELISA assay). In certain embodiments, an antibody or antigen binding fragment thereof provided herein is capable of specifically binding to the 4-1BB binding portion of ATG-101 (e.g., as measured by an ELISA assay). In certain embodiments, an antibody or antigen-binding fragment thereof provided herein is capable of specifically binding to the PD-L1 binding portion and 4-1BB binding portion of ATG-101 (e.g., as measured by an ELISA assay).
In another aspect, the present disclosure provides antibodies and antigen-binding fragments thereof that compete with ATG-101 for binding to PD-L1 and/or 4-1 BB.
The ability to "compete with ATG-101 for binding to" a target refers to the ability of a primary antibody or antigen-binding fragment thereof to inhibit the interaction of binding between the target (e.g., PD-L1 and/or 4-1 BB) and ATG-101 to any detectable extent. In certain embodiments, an antibody or antigen binding fragment that competes for binding to PD-L1 and/or 4-1BB inhibits the interaction of binding between PD-L1 and/or 4-1BB and ATG-101 by at least 85% or at least 90%. In certain embodiments, the inhibition may be greater than 95% or greater than 99%.
Exemplary antibodies
In certain embodiments, the disclosure provides antibodies or antigen binding fragments thereof comprising:
one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20, 27, 34, 41, 48 and 55; and/or
One or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.7, 14, 21, 28, 35, 42, 49 and 56.
The CDR boundaries of a VH region or VL region can be defined or determined by methods known to those skilled in the art, provided that the amino acid sequence of the VH region or VL region is known. For example, CDR boundaries of an antibody or antigen binding fragment thereof may be defined or determined by Kabat, IMGT, chothia or Al-Lazikani rules (Al-Lazikani, b., chothia, c., lesk, a.m., journal of molecular biology, 273 (4), 927 (1997); chothia, C.et Al, 12 months 5; 186 (3): 651-63 (1985), chothia, C.and Lesk, A.M., journal of molecular biology, 196,901 (1987), chothia, C.et Al, nature, 12 months 21-28; 342 (6252): 877-83 (1989), kabat E.A. et Al, protein sequences of immunological significance (Sequences of Proteins of immunological Interest), 5 th edition public health agency (Public Health Service), national institutes of health (National Institutes of Health), besseda (Bethesda, md.) (1991), marie-Paule Lefranc et Al, development and comparison immunology (Developmental and Comparative Immunology), 27:55-77 (2003), marie-Paule Leflanc et Al, immune group study (Immunome Research), 1 (3), (2005-Paul) and (2015), leul, mahala, B.35, and (2015). In some embodiments, CDR boundaries of an antibody or antigen binding fragment thereof provided herein are determined according to the Kabat rules. In some embodiments, CDR boundaries of an antibody or antigen binding fragment thereof provided herein are determined according to IMGT rules. In some embodiments, CDR boundaries of an antibody or antigen binding fragment thereof provided herein are determined according to Chothia rules. In some embodiments, the CDR boundaries of an antibody or antigen binding fragment thereof provided herein are determined according to the Al-Lazikani rule.
In certain embodiments, the disclosure provides antibodies or antigen-binding fragments thereof that include one or more (e.g., 1, 2, 3, 4, 5, or 6) CDR sequences of antibodies 9D6E11, 10F10G7, 27E8A8, 31B6G8, 58H6F8, 63C9C12, 75H9F7, or 50D6E 10.
As used herein, antibody "9D6E11" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID No. 6 and a light chain variable region having the sequence of SEQ ID No. 7.
As used herein, antibody "10F10G7" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 13 and a light chain variable region having the sequence of SEQ ID NO. 14.
As used herein, antibody "27E8A8" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 20 and a light chain variable region having the sequence of SEQ ID NO. 21.
As used herein, antibody "31B6G8" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 27 and a light chain variable region having the sequence of SEQ ID NO. 28.
As used herein, antibody "58H6F8" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 34 and a light chain variable region having the sequence of SEQ ID NO. 35.
As used herein, antibody "63C9C12" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 41 and a light chain variable region having the sequence of SEQ ID NO. 42.
As used herein, antibody "75H9F7" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID No. 48 and a light chain variable region having the sequence of SEQ ID No. 49.
As used herein, antibody "50D6E10" refers to a mouse monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO. 55 and a light chain variable region having the sequence of SEQ ID NO. 56.
Specific amino acid sequences of the heavy chain variable region and the light chain variable region of each of the exemplary antibodies described above are shown in table 4 below.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:6 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 7.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:13 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 14.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:20 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 21.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:27 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 28.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:34 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 35.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:41 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 42.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:48 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 49.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs (HCDR 1, HCDR2, and HCDR 3) comprising a VH region sequence as set forth in SEQ ID NO:55 and three light chain CDRs (LCDR 1, LCDR2, and LCDR 3) comprising a VL region sequence as set forth in SEQ ID NO: 56.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises at least one (e.g., 1, 2, or 3) heavy or light chain CDR comprising an amino acid sequence selected from the group consisting of: 1, 2, 3, 4, NAK, 5, 8, 9, 10, 11, RAN, 12, 15, 16, 17, 18, AAS, 19, 22, 23, 24, 25, AAS, 26, 29, 30, 31, 32, STS, 33, 36, 37, 38, 39, NAK, 40, 43, 44, 45, 46, NAK, 47, 50, 51, 52, 53, QMS and 54.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a VH region comprising one or two or three of HCDR1, HCDR2, and HCDR3, the HCDR1, HCDR2, and HCDR3 comprising an amino acid sequence selected from the group consisting of: 1, 2, 3, 8, 9, 10, 15, 16, 17, 22, 23, 24, 29, 30, 31, 36, 37, 38, 43, 44, 45, 50, 51 and 52.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a VL region comprising one or two or three of LCDR1, LCDR2, and LCDR3, the LCDR1, LCDR2, and LCDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 4, NAK, 5, 11, RAN, 12, 18, AAS, 19, 25, AAS, 26, 32, STS, 33, 39, NAK, 40, 46, NAK, 47, 53, QMS and 54.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises HCDR1, HCDR2, and HCDR3, the HCDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs 1, 8, 15, 22, 29, 36, 43 and 50; the HCDR2 comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs 2, 9, 16, 23, 30, 37, 44 and 51; the HCDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs 3, 10, 17, 24, 31, 38, 45 and 52.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises an LCDR1, an LCDR2, and an LCDR3, the LCDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS 4, 11, 18, 25, 32, 39, 46 and 53; the LCDR2 comprises an amino acid sequence selected from the group consisting of: NAK, RAN, AAS, AAS, STS, NAK, NAK and QMS; the LCDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS 5, 12, 19, 26, 33, 40, 47 and 54.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises:
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 1, said HCDR2 comprising an amino acid sequence of SEQ ID No. 2, said HCDR3 comprising an amino acid sequence of SEQ ID No. 3;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 8, said HCDR2 comprising an amino acid sequence of SEQ ID No. 9, said HCDR3 comprising an amino acid sequence of SEQ ID No. 10;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 15, said HCDR2 comprising an amino acid sequence of SEQ ID No. 16, said HCDR3 comprising an amino acid sequence of SEQ ID No. 17;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 22, said HCDR2 comprising an amino acid sequence of SEQ ID No. 23, said HCDR3 comprising an amino acid sequence of SEQ ID No. 24;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 29, said HCDR2 comprising an amino acid sequence of SEQ ID No. 30, said HCDR3 comprising an amino acid sequence of SEQ ID No. 31;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 36, said HCDR2 comprising an amino acid sequence of SEQ ID No. 37, said HCDR3 comprising an amino acid sequence of SEQ ID No. 38;
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 43, said HCDR2 comprising an amino acid sequence of SEQ ID No. 44, and said HCDR3 comprising an amino acid sequence of SEQ ID No. 45; or (b)
HCDR1, HCDR2 and HCDR3, said HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 50, said HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 51 and said HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 52.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises:
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises an amino acid sequence as shown in SEQ ID NO. 4, LCDR2 comprises an amino acid sequence as shown in NAK, and LCDR3 comprises an amino acid sequence as shown in SEQ ID NO. 5;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO. 11, LCDR2 comprises the amino acid sequence shown in RAN, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO. 12;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown as SEQ ID NO. 18, LCDR2 comprises the amino acid sequence shown as AAS, and LCDR3 comprises the amino acid sequence shown as SEQ ID NO. 19;
LCDR1, LCDR2 and LCDR3, wherein LCDR1 comprises the amino acid sequence shown in SEQ ID NO. 25, LCDR2 comprises the amino acid sequence shown in AAS, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO. 26;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 32, said LCDR2 comprising an amino acid sequence shown as STS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 33;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, and said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO:46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 47; or (b)
LCDR1, LCDR2 and LCDR3, said LCDR1 comprising the amino acid sequence shown as SEQ ID NO:53, said LCDR2 comprising the amino acid sequence shown as QMS and said LCDR3 comprising the amino acid sequence shown as SEQ ID NO: 54.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 1, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 2, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 3, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 4, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 5;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 12;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 15, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 16, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 17, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 18, said LCDR2 comprising an amino acid sequence shown as AAS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 19;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence of SEQ ID No. 22, said HCDR2 comprising an amino acid sequence of SEQ ID No. 23, said HCDR3 comprising an amino acid sequence of SEQ ID No. 24, said LCDR1 comprising an amino acid sequence of SEQ ID No. 25, said LCDR2 comprising an amino acid sequence of AAS, said LCDR3 comprising an amino acid sequence of SEQ ID No. 26;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 36, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 37, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 38, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 43, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 44, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 45, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 46, said LCDR2 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 47; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 54.
The heavy chain (denoted "H") variable region, light chain (denoted "L") variable region, HCDR and LCDR SEQ ID NOs of each of the 8 monoclonal antibodies are shown in table 2 below. CDR boundaries as described herein are defined or determined by IMGT rules, unless otherwise specified. The amino acid sequences of each CDR of 8 exemplary monoclonal antibodies are shown in table 3 below. The amino acid sequences of each VH and VL of 8 exemplary monoclonal antibodies are shown in table 4 below.
TABLE 2 VH, VL, HCDR and LCDR SEQ ID NOs of 8 exemplary monoclonal antibodies
TABLE 3 amino acid sequence of each CDR of 8 exemplary monoclonal antibodies
/>
/>
TABLE 4 amino acid sequences of each VH and VL of 8 exemplary monoclonal antibodies
/>
It is contemplated that each of the 8 exemplary monoclonal antibodies can bind to ATG-101, and that antigen binding specificity is provided primarily by the CDR1, CDR2, and CDR3 regions, the HCDR1, HCDR2, and HCDR3 sequences and the LCDR1, LCDR2, and LCDR3 sequences of each of the 8 exemplary monoclonal antibodies can be "mixed and matched" (i.e., CDRs from different antibodies can be mixed and matched, but each antibody must contain HCDR1, HCDR2, and HCDR3, as well as LCDR1, LCDR2, and LCDR 3) to produce an ATG-101 binding molecule of the present disclosure. Binding assays as described above and in the examples can be used to test the binding of such "mixed and matched" antibodies to ATG-101. Preferably, when VH CDR sequences are mixed and matched, HCDR1 sequences, HCDR2 sequences and/or HCDR3 sequences from a particular VH sequence are replaced with structurally similar CDR sequences. Likewise, when VL CDR sequences are mixed and matched, LCDR1, LCDR2 and/or LCDR3 sequences from a particular VL sequence are preferably replaced by structurally similar CDR sequences. For example, HCDR1 of antibodies 9D6E11 and 27E8A8 share some structural similarity, and are therefore easy to mix and match. It will be apparent to those skilled in the art that novel VH and VL sequences can be generated by substituting one or more VH and/or VL CDR sequences with structurally similar sequences from the CDR sequences disclosed herein for 8 exemplary monoclonal antibodies.
CDRs are known to be responsible for antigen binding. However, not all 6 CDRs have been found to be indispensable or unchangeable. In other words, one or more CDRs of each of the 8 exemplary monoclonal antibodies can be replaced or altered or modified, but substantially retain specific binding affinity for ATG-101.
In certain embodiments, the antibodies and antigen binding fragments provided herein comprise the heavy chain CDR3 sequence of one of antibodies 9D6E11, 10F10G7, 27E8A8, 31B6G8, 58H6F8, 63C9C12, 75H9F7, or 50D6E 10. In certain embodiments, the antibodies and antigen binding fragments provided herein comprise a heavy chain CDR3 sequence selected from the group consisting of seq id nos: SEQ ID NOs 3, 10, 17, 24, 31, 38, 45 and 52. The heavy chain CDR3 region is centered in the antigen binding site and is therefore considered to be most in contact with the antigen and provides the antibody with the most free energy of affinity for the antigen. It is also believed that heavy chain CDR3 is the CDR of antigen binding sites most diverse so far in length, amino acid composition and conformation by a variety of mechanisms (Tonegawa S., nature) 302:575-81). The diversity of heavy chain CDR3 is sufficient to generate most antibody specificities (Xu JL, davis MM. immunity 13:37-45) and ideal antigen binding affinities (Schier R et al J Mol biol) 263:551-67).
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a VH region having an amino acid sequence as set forth in SEQ ID No. 6, 13, 20, 27, 34, 41, 48, or 55 or a homologous sequence having at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) sequence identity to SEQ ID No. 6, 13, 20, 27, 34, 41, 48, or 55.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a VL region having an amino acid sequence as set forth in SEQ ID No. 7, 14, 21, 28, 35, 42, 49, or 56 or a homologous sequence having at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) sequence identity to SEQ ID No. 7, 14, 21, 28, 35, 42, 49, or 56.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a VH/VL amino acid sequence pair selected from the group consisting of: SEQ ID NOS 6 and 7, 13 and 14, 20 and 21, 27 and 28, 34 and 35, 41 and 42, 48 and 49, and 55 and 56.
In certain embodiments, the antibodies and antigen-binding fragments thereof provided herein include suitable Framework Region (FR) sequences, so long as the antibodies and antigen-binding fragments thereof can specifically bind to ATG-101. The CDR sequences provided in table 3 above were obtained from a mouse antibody, but the CDR sequences may be grafted to any suitable FR sequences of any suitable species, such as mouse, human, rat, rabbit, etc., using suitable methods known in the art, such as recombinant techniques.
In certain embodiments, the antibodies and antigen binding fragments thereof provided herein are humanized. It is desirable for the humanized antibody or antigen-binding fragment thereof to have reduced immunogenicity in humans. Humanized antibodies are chimeric in their variable regions because the non-human CDR sequences are grafted to human or substantially human FR sequences. Humanization of antibodies or antigen-binding fragments can be performed essentially by substituting non-human (e.g., murine) CDR genes for corresponding human CDR genes in human immunoglobulin genes (see, e.g., jones et al (1986) Nature 321:522-525; riechmann et al (1988) Nature 332:323-327; verhoeyen et al (1988) Science 239:1534-1536).
Suitable human heavy and light chain variable domains can be selected using methods known in the art to achieve this. In an illustrative example, a "best fit" approach may be used in which a human sequence closest to the non-human query sequence is identified against a database of known human variable domain sequences or BLAST non-human (e.g., rodent) antibody variable domain sequences, and used as a human framework for grafting non-human CDR sequences (see, e.g., sims et al, (1993) journal of immunology (j. Immunol.)) (151:2296; chothia et al (1987) journal of molecular biology 196:901). Alternatively, frameworks derived from the consensus sequences of all human antibodies can be used to implant non-human CDRs (see, e.g., carter et al (1992) Proc. Natl. Acad. Sci. USA), 89:4285; presta et al (1993) J.Immunol., 151:2623).
In some embodiments, the antibodies or antigen binding fragments thereof provided herein are humanized. In certain embodiments, a humanized antibody or antigen binding fragment thereof provided herein consists of substantially fully human sequences, except for non-human CDR sequences. In some embodiments, the variable region FR and constant region (if present) are derived entirely or substantially from human immunoglobulin sequences. The human FR sequence and the human constant region sequence may be derived from different human immunoglobulin genes, e.g., the FR sequence is derived from one human antibody and the constant region is derived from another human antibody. In some embodiments, the humanized antibody or antigen binding fragment thereof comprises human heavy chains HFR1, HFR2, HFR3 and HFR4 and/or light chains LFR1, LFR2, LFR3 and LFR4.
In some embodiments, the human-derived FR region may include the same amino acid sequence as the human immunoglobulin from which it is derived. In some embodiments, one or more amino acid residues of the human FR are substituted with corresponding residues from the parent non-human antibody. In certain embodiments, this may be desirable to bring the humanized antibody or fragment thereof in close proximity to the non-human parent antibody structure, thereby optimizing binding properties (e.g., increasing binding affinity). In certain embodiments, a humanized antibody or antigen binding fragment thereof provided herein comprises no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue substitutions in each of a plurality of human FR sequences, or no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue substitutions in all FR sequences of a heavy or light chain variable domain. In some embodiments, such changes in amino acid residues may be present in only the heavy chain FR region, only the light chain FR region, or in both chains. In certain embodiments, one or more amino acids of the human FR sequence are randomly mutated to increase binding affinity. In certain embodiments, one or more amino acids of the human FR sequence are back mutated to the corresponding amino acids of the parent non-human antibody to increase binding affinity.
In some embodiments, antibodies and antigen binding fragments provided herein include all or a portion of a heavy chain variable domain and/or all or a portion of a light chain variable domain. In one embodiment, the antibody or antigen binding fragment thereof provided herein is a single domain antibody consisting of all or a portion of the heavy chain variable domains provided herein. More information about such single domain antibodies is available in the art (see, e.g., U.S. patent No. 6,248,516).
In certain embodiments, an antibody or antigen binding fragment thereof provided herein further comprises an Fc region. In certain embodiments, an antibody or antigen binding fragment thereof provided herein further comprises an Fc region of a human immunoglobulin (Ig). In certain embodiments, an antibody or antigen-binding fragment thereof provided herein further comprises a constant region, optionally further comprising a heavy chain and/or light chain constant region. In certain embodiments, the heavy chain constant region comprises a CH1, hinge, and/or CH2-CH3 region (or optionally a CH2-CH3-CH4 region). In certain embodiments, an anti-drug antibody or antigen-binding fragment thereof provided herein comprises a heavy chain constant region of human IgG1, igG2, igG3, igG4, igA1, igA2, or IgM. In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises a lambda (lambda) light chain or a kappa (kappa) light chain. The constant regions of the antibodies or antigen binding fragments thereof provided herein may be identical to the wild-type constant region sequence or may differ in one or more mutations.
In certain embodiments, the heavy chain constant region comprises an Fc region. The Fc region is known to mediate effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of antibodies. In certain embodiments, an antibody or antigen binding fragment thereof provided herein further comprises an Fc region of a human or mouse immunoglobulin (Ig). In certain embodiments, the antibodies or antigen binding fragments thereof provided herein further comprise an Fc region of a human or mouse IgG. In certain embodiments, the Fc region is derived from IgG1, igG2, igG3, or IgG4.
The Fc regions of different Ig isotypes have different abilities to induce effector functions. For example, the Fc regions of IgG1 and IgG3 have been recognized to induce both ADCC and CDC more effectively than the Fc regions of IgG2 and IgG4. In certain embodiments, the antibodies and antigen binding fragments thereof provided herein comprise an Fc region of an IgG1 or IgG3 isotype that can induce ADCC or CDC; or alternatively, a constant region of the IgG4 or IgG2 isotype, which has a reduced or depleted effector function. In some embodiments, the Fc region is derived from human IgG1. In some embodiments, the Fc region is derived from human IgG1 having enhanced effector function. In some embodiments, the Fc region includes an amino acid sequence as set forth in SEQ ID NO. 75.
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:75)
In some embodiments, the Fc region includes the amino acid sequence shown as SEQ ID NO. 76.
AKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQS
DLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFP
PKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVS
ELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVS
LTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK(SEQ ID NO:76)
In certain embodiments, the antibodies or antigen binding fragments thereof provided herein have a specific binding affinity for ATG-101, which is sufficient to provide diagnostic and/or therapeutic uses.
The antibodies or antigen binding fragments thereof provided herein can be monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies, chimeric antibodies, recombinant antibodies, bispecific antibodies, multispecific antibodies, labeled antibodies, bivalent antibodies, anti-idiotype antibodies, or fusion proteins. Recombinant antibodies are antibodies that are produced in vitro, rather than in an animal, using recombinant methods.
In certain embodiments, the present disclosure provides antibodies or antigen-binding fragments thereof that compete with the antibodies or antigen-binding fragments thereof provided herein for binding to ATG-101. In certain embodiments, the disclosure provides antibodies or antigen binding fragments thereof that compete with any of antibodies 9D6E11, 10F10G7, 27E8A8, 31B6G8, 58H6F8, 63C9C12, 75H9F7, and 50D6E10 for binding to ATG-101. In some embodiments, the disclosure provides antibodies or antigen-binding fragments thereof that compete for the same epitope as the antibodies or antigen-binding fragments provided herein.
As used herein, the ability to "block binding" or "compete binding" refers to the ability of an antibody or antigen binding fragment to inhibit the interaction of binding between two molecules (e.g., ATG-101 and an antibody of the disclosure) to any detectable extent. In certain embodiments, an antibody or antigen binding fragment thereof that blocks binding between two molecules inhibits the interaction of binding between two molecules by at least 85% or at least 90%. In certain embodiments, the inhibition may be greater than 95% or greater than 99%.
One of skill in the art will recognize that by determining whether a human monoclonal antibody prevents binding of an antibody of the present disclosure to ATG-101, it can be determined, without undue experimentation, whether the human monoclonal antibody binds to the same epitope as an antibody of the present disclosure (e.g., mouse monoclonal antibody 9D6E11, 10F10G7, 27E8A8, 31B6G8, 58H6F8, 63C9C12, 75H9F7, or 50D6E 10). If the test antibody competes with the antibodies of the disclosure, as indicated by reduced binding of the antibodies of the disclosure to ATG-101, both antibodies bind to the same or closely related epitope. Alternatively, if the binding of the test antibody to ATG-101 is inhibited by an antibody of the present disclosure, both antibodies bind to the same or closely related epitope.
Antibody variants
Antibodies and antigen binding fragments thereof provided herein also encompass various variants of the antibody sequences provided herein.
In certain embodiments, the antibody variants comprise one or more amino acid residue substitutions or modifications, but still retain specific binding affinity for ATG-101. In certain embodiments, at least one of the substitutions or modifications is located in one or more CDR sequences of the VH region or the VL region. In certain embodiments, at least one of the substitutions or modifications is located in one or more non-CDR sequences of the VH region or the VL region. In certain embodiments, the antibodies of the present disclosure, or antigen-binding fragments thereof, further comprise one or more unnatural amino acid (NNAA) substitutions. In certain embodiments, the NNAA is capable of being conjugated.
For example, the antibody variants include one or more of the CDR sequences provided in table 3 above, one or more of the non-CDR sequences of the heavy chain variable region or the light chain variable region provided in table 4 above, and/or one or more amino acid residue substitutions or modifications in the constant region (e.g., fc region). Such variants retain the binding specificity of their parent antibody for ATG-101 but have one or more of the desired properties conferred by the modification or substitution. For example, antibody variants may have improved antigen binding affinity, improved glycosylation pattern, reduced glycosylation risk, reduced deamination, enhanced effector function, improved FcRn receptor binding, increased pharmacokinetic half-life, pH sensitivity, and/or compatibility with conjugation (e.g., one or more introduced cysteine residues), and the like.
The parent antibody sequences may be screened using methods known in the art, such as "alanine scanning mutagenesis", to identify suitable or preferred residues to be modified or substituted (see, e.g., cunningham and Wells (1989), science, 244:1081-1085). Briefly, target residues (e.g., charged residues such as Arg, asp, his, lys and Glu) can be identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine), and modified antibodies generated and screened for a property of interest. If a representation at a particular amino acid position exhibits a functional change of interest, that position can be identified as a potential residue for modification or substitution. The potential residues may be further assessed by substitution with another residue (e.g., a cysteine residue, a positively charged residue, etc.).
Affinity variants
The affinity variant of an antibody may contain one or more CDR sequences, one or more FR sequences provided in table 3 above, or modifications or substitutions in the heavy or light chain variable region sequences provided in table 4 above. The skilled artisan can readily identify FR sequences based on the CDR sequences in table 3 above and the variable region sequences in table 4 above, as it is well known in the art that in the variable region, the CDR regions flank two FR regions. The affinity variant retains the specific binding affinity of the parent antibody for ATG-101 or even has a higher specific binding affinity for ATG-101 than the parent antibody. In certain embodiments, at least one (or all) of the substitutions in the CDR sequences, FR sequences, or variable region sequences comprise conservative substitutions.
Those skilled in the art will appreciate that one or more amino acid residues may be substituted in the CDR sequences provided in table 3 above and the variable region sequences provided in table 4 above, but the resulting antibody or antigen binding fragment still retains binding affinity or binding capacity for ATG-101, or even has improved binding affinity or binding capacity. Various methods known in the art may be used to achieve this. For example, a library of antibody variants (e.g., fab or scFv variants) can be generated and expressed using phage display techniques, which are then screened for affinity for binding to ATG-101. For another example, computer software may be used to virtually mimic the binding of an antibody to ATG-101 and identify the amino acid residues on the antibody that form the binding interface. Such residues may be avoided in the substitution to prevent binding affinity from decreasing, or may be targeted for substitution to obtain stronger binding.
In certain embodiments, a humanized antibody or antigen-binding fragment thereof provided herein comprises one or more CDR sequences in a CDR sequence and/or one or more amino acid residue substitutions in one or more FR sequences in an FR sequence. In certain embodiments, the affinity variants comprise no more than 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substitutions in total in the CDR sequence and/or FR sequence.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises 1, 2, or 3 CDR sequences that have at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the sequences listed in table 3 above, but still retain specific binding affinity for ATG-101 at a similar or even higher level relative to its parent antibody.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises one or more variable region sequences that have at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the sequences listed in table 4 above, but still retain specific binding affinity for ATG-101 at a similar or even higher level relative to its parent antibody. In some embodiments, from 1 to 10 amino acids are substituted, inserted, or deleted in total in the variable region sequences listed in table 4 above. In some embodiments, the substitution, insertion, or deletion occurs in a region outside of the CDRs (e.g., in the FR).
Glycosylation variants
The antibodies or antigen-binding fragments thereof provided herein also encompass glycosylated variants that may be obtained to increase or decrease the degree of glycosylation of the antibodies or antigen-binding fragments thereof.
The antibodies or antigen binding fragments thereof provided herein may include one or more modifications that introduce or remove glycosylation sites. Glycosylation sites are amino acid residues having side chains to which carbohydrate moieties (e.g., oligosaccharide structures) may be attached. Glycosylation of antibodies is typically N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue (e.g., an asparagine residue in a tripeptide sequence such as asparagine-X-serine and asparagine-X-threonine), where X is any amino acid other than proline. O-linked glycosylation refers to the attachment of one of N-acetylgalactosamine, galactose or xylose to a hydroxy amino acid, most commonly serine or threonine. The natural glycosylation site can be conveniently removed, for example by altering the amino acid sequence such that one of the above tripeptide sequences (for an N-linked glycosylation site) or serine or threonine residues (for an O-linked glycosylation site) present in the sequence is substituted. New glycosylation sites can be created in a similar manner by introducing such tripeptide sequences or serine or threonine residues.
Cysteine engineered variants
Antibodies or antigen binding fragments thereof provided herein also encompass cysteine engineered variants comprising one or more introduced free cysteine amino acid residues.
The free cysteine residue is a cysteine residue that is not part of a disulfide bond. Cysteine engineered variants can be used to conjugate, for example, cytotoxic and/or imaging compounds, labels or radioisotopes, etc., at the site of the engineered cysteine via, for example, maleimide or haloacetyl groups. Methods for engineering antibodies or antigen binding fragments thereof to introduce free cysteine residues are known in the art, see, e.g., WO2006/034488.
Fc variants
Antibodies and antigen binding fragments provided herein also encompass Fc variants comprising one or more amino acid residue modifications or substitutions at their Fc region and/or hinge region.
In certain embodiments, the antibody or antigen binding fragment thereof comprises one or more amino acid substitutions that improve pH-dependent binding to neonatal Fc receptor (FcRn). Such variants may have an extended pharmacokinetic half-life in that it binds to FcRn at acidic pH, freeing it from degradation in lysosomes, and subsequently being transferred and released extracellularly. Methods for engineering antibodies and antigen binding fragments thereof to increase binding affinity to FcRn are well known in the art, see, e.g., vaughn, d. Et al, structure, 6 (1): 63-73,1998; kontermann, R.et al, antibody engineering (Antibody Engineering), volume 1, chapter 27. Fc regions were engineered to improve PK (Engineering of the Fc region for improved PK), published by Springer, 2010; yeung, Y.et al, cancer Research, 70:3269-3277 (2010); and Hinton, P.et al, J.Immunol.176:346-356 (2006).
In certain embodiments, the antibody or antigen binding fragment thereof comprises one or more amino acid substitutions that alter ADCC. Certain amino acid residues at the CH2 domain of the Fc region may be substituted to provide enhanced ADCC activity. Alternatively or additionally, the carbohydrate structure on the antibody may be altered to enhance ADCC activity. Methods for altering ADCC activity by antibody engineering have been described in the art, see for example, shields RL. et al, journal of biochemistry (Jbiol chem.) 2001 276 (9): 6591-604; idusiogie EE et al, J.Immunol. 2000.164 (8): 4178-84; steurer W et al J.Immunology 1995,155 (3): 1165-74; idusibie EE et al J.Immunol.2001, 166 (4): 2571-5; lazar GA. et al, proc. Natl. Acad. Sci. USA (PNAS), 2006,103 (11): 4005-4010; ryan MC. et al, molecular cancer therapy (mol. Cancer ter.), 2007,6:3009-3018; richards JO et al, molecular Cancer therapy (Mol Cancer Ther.) 2008,7 (8): 2517-27; shields R.L. et al, J.Biol.chem., 2002,277:26733-26740; shinkawa T.et al, (J. Biol. Chem.) 2003,278:3466-3473.
In certain embodiments, the antibody or antigen binding fragment thereof comprises one or more amino acid substitutions that alter CDC, e.g., by improving or reducing C1q binding and/or CDC (see, e.g., WO99/51642; duncan and Winter Nature (Science) 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821); and WO94/29351 regarding other examples of variants of Fc regions. One or more amino acids selected from amino acid residues 329, 331 and 322 of the Fc region may be substituted with a different amino acid residue to alter C1q binding and/or enhance CDC (see U.S. patent No. 6,194,551 to Idusogie et al). One or more amino acid substitutions may also be introduced to alter the ability of the antibody to fix complement (see PCT publication WO94/29351 to Bodmer et al).
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises one or more amino acid substitutions at positions 234 and/or 235 (according to EP numbering) of a human immunoglobulin (e.g., igG 1). In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises two amino acid substitutions at positions 234 and 235 (numbered according to EP) in a human immunoglobulin (e.g., igG 1). In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises L234A and L235A (numbering according to EU) amino acid substitutions.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein includes one or more amino acid substitutions in the interface of the Fc region to facilitate promotion and/or promote heterodimerization. These modifications include introducing a protuberance into a first Fc polypeptide and introducing a cavity into a second Fc polypeptide, wherein the protuberance can be positioned in the cavity so as to facilitate interaction of the first Fc polypeptide with the second Fc polypeptide to form a heterodimer or complex. Methods of producing antibodies with these modifications are known in the art, for example, as described in U.S. Pat. No. 5,731,168.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises an amino acid substitution at position 366 (according to EP numbering) of a first Fc polypeptide and comprises one, two, or three amino acid substitutions at one, two, or three positions 366, 368, and 407 (according to EP numbering) of a second Fc polypeptide. In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a T366W (according to EP numbering) substitution of a first Fc polypeptide and comprises a T366s+l368a+y407V (according to EP numbering) substitution of a second Fc polypeptide.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein further comprises one or more amino acid substitutions of a first Fc polypeptide and comprises one or more amino acid substitutions of a second Fc polypeptide, thereby introducing a non-native disulfide bond between the two Fc polypeptides. For example, an antibody or antigen-binding fragment thereof provided herein includes an amino acid substitution at position 354 (according to EU numbering) of a first Fc polypeptide and includes an amino acid substitution at position 349 (according to EU numbering) of a second Fc polypeptide. In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises an S354C (according to EP numbering) substitution of a first Fc polypeptide and comprises a Y349C (according to EP numbering) substitution of a second Fc polypeptide.
In certain embodiments, an antibody or antigen-binding fragment thereof provided herein comprises a first Fc polypeptide comprising an amino acid sequence as set forth in SEQ ID No. 77 and a second Fc polypeptide comprising an amino acid sequence as set forth in SEQ ID No. 78.
KTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:77)
KTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:78)
Antigen binding fragments
Antigen binding fragments are also provided herein. Various types of antigen binding fragments are known in the art and can be developed based on the antibodies provided herein, including, for example, exemplary antibodies whose CDRs are shown in table 3 above and whose variable sequences are shown in table 4, and different variants thereof (e.g., affinity variants, glycosylation variants, fc variants, cysteine engineered variants, etc.).
In certain embodiments, the antigen-binding fragments provided herein are bifunctional antibodies (diabodies), fab ', F (ab') 2 Fd, fv fragment, disulfide stabilized Fv fragment (dsFv), (dsFv) 2 Bispecific dsFv (dsFv-dsFv'), disulfide-stabilized bifunctional antibody (ds diabody), single chain antibody molecule [ ]scFv), scFv dimers (bivalent bifunctional antibodies), multispecific antibodies, camelized single domain antibodies, nanobodies, domain antibodies, and bivalent domain antibodies.
Such antigen binding fragments can be produced using a variety of techniques. Exemplary methods include enzymatic digestion of intact antibodies (see, e.g., morimoto et al, journal of biochemistry and biophysics methods (Journal of Biochemical and Biophysical Methods) 24:107-117 (1992), and Brennan et al, science 229:81 (1985)), recombinant expression by host cells such as E.coli (e.g., for Fab, fv and ScFv antibody fragments), screening from phage display libraries (e.g., for ScFv) as discussed above, and chemical coupling of two Fab '-SH fragments to form F (ab') 2 Fragments (Carter et al, biology/Technology (Bio/Technology) 10:163-167 (1992)). Other techniques for producing antibody fragments will be apparent to those skilled in the art.
In certain embodiments, the antigen binding fragment is an scFv. The production of scFv is described below: for example WO 93/16185; U.S. patent No. 5,571,894; and No. 5,587,458. ScFv can be fused at the amino-or carboxy-terminus to an effector protein to provide a fusion protein (see e.g., antibody engineering, borrebaeck editions).
In certain embodiments, the antibodies or antigen binding fragments thereof provided herein are bivalent, tetravalent, hexavalent, or multivalent. Any molecule that is more than divalent is considered multivalent and encompasses, for example, trivalent, tetravalent, hexavalent, and the like.
A bivalent molecule may be monospecific if both binding sites specifically bind to the same antigen or the same epitope. In certain embodiments, this provides for stronger binding to an antigen or epitope than the monovalent counterpart. Similarly, multivalent molecules may also be monospecific. In certain embodiments, in a bivalent or multivalent antigen binding portion, the first valence of the binding site and the second valence of the binding site are structurally identical (i.e., have the same sequence) or structurally different (i.e., have different sequences, but have the same specificity).
Bivalent may also be bispecific if both binding sites are specific for different antigens or epitopes. The same applies to multivalent molecules. For example, a trivalent molecule may be bispecific when two binding sites are monospecific for a first antigen (or epitope) and a third binding site is specific for a second antigen (or epitope).
Bispecific or multispecific antibodies
In certain embodiments, the antibodies or antigen binding fragments thereof provided herein are bispecific or multispecific. In certain embodiments, an antibody or antigen-binding fragment thereof provided herein is further linked to a second functional moiety or antigen-binding fragment thereof having a binding specificity different from that of the antibody. In some embodiments, the bispecific or multispecific antibodies and antigen-binding fragments thereof provided herein have a first specificity for ATG-101 and a second specificity. In some embodiments, the second specificity is for ATG-101 but for a different epitope.
In certain embodiments, the second specificity is for a tumor-associated antigen or epitope thereof. The term "tumor-associated antigen" refers to an antigen that is present or presentable on the surface of tumor cells, as well as on or within tumor cells. In some embodiments, the tumor-associated antigen can only be presented by tumor cells, but not by normal cells (i.e., non-tumor cells). In some other embodiments, the tumor-associated antigen may be expressed exclusively on tumor cells or may represent a tumor-specific mutation compared to non-tumor cells. In some other embodiments, the tumor-associated antigen may be found in both tumor cells and non-tumor cells, but is over-expressed on tumor cells when compared to non-tumor cells, or may be used for antibody binding in tumor cells due to the less compact structure of tumor tissue compared to non-tumor tissue. In some embodiments, the tumor-associated antigen is located on the vasculature of the tumor.
In certain embodiments, a bispecific antibody or multispecific antibody provided herein, or antigen-binding fragment thereof, is capable of specifically binding to one or more (e.g., 1, 2, 3, 4, 5, or more) additional antigens other than ATG-101, or to a second epitope on ATG-101. In certain embodiments, the one or more additional antigens other than ATG-101 are selected from the group consisting of: KRAS, ERK, XPO1, mTORC1/2, PAK4, NAMPT, ATR, EGFR, FGFR, VEGF, LILRB (e.g., LILRB1, LILRB2, LILRB3, LILRB4, LILRB 5), C-MET, her2, her3, CTLA4, GITA, CD112R, CD2, CD3, CD7, CD16, CD19, CD20, CD24, CD27, CD30, CD34, CD37, CD39, CD70, CD73, CD83, CD28, CD80 (B7-1), CD86 (B7-2), CD40L (CD 154), CD47, sirpa, CD122, CD137L, OX (CD 134), OX40L (CD 252), BCMA (e.g., BCMA 02), PSMA, CLDN18 (e.g., CLDN 18.2), NKG2C, 4-1BB, LIGHT, PVRIG, SLAMF7, HVEM, BAFFR, ICAM-1, 2B4, LFA-1, GITR, ICOS (CD 278), icosolg (CD 275), LAG3 (CD 223), A2AR, B7-H3 (CD 276), B7-H4 (VTCN 1), B7-H5, BTLA (CD 272), CD160, CTLA-4 (CD 152), GPRC5D, IDO (e.g., IDO1, IDO 2), TDO, KIR, LAIR-1, NOX2, PD-1, PD-L2, TIM-3, VISTA, SIGLEC-7 (CD 328), SIGLEC-9 (CD 329), SIGLEC-15, git, PVR (CD 155), and tgfβ.
In certain embodiments, a bispecific antibody or multispecific antibody or antigen-binding fragment thereof provided herein is capable of specifically binding to a PD-L1 binding portion and a 4-1BB binding portion of ATG-101.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises:
i. one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20 and 27;
one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: 34, 41, 48 and 55;
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS 7, 14, 21 and 28; and
one or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.35, 42, 49 and 56.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein comprises:
i. HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 4, LCDR2 comprising the amino acid sequence shown in NAK, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 5, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 29
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 30, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 31, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:
32, an LCDR1 comprising an amino acid sequence as shown in STS, an LCDR2 comprising an amino acid sequence as shown in SEQ ID No. 33;
HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 1, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 2, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 3, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 4, LCDR2 comprising the amino acid sequence shown as NAK, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 5, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 36
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 37, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 38, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:
39, an LCDR1 comprising an amino acid sequence shown as NAK, an LCDR2 comprising an amino acid sequence shown as SEQ ID No. 40, and an LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 1, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 2, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 3, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 4, LCDR2 comprising the amino acid sequence shown as NAK, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 5, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 43
HCDR1 of the amino acid sequence shown, HCDR2 comprising the amino acid sequence shown as SEQ ID NO:44, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:45, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:44
LCDR1 of the amino acid sequence shown as NO. 46, LCDR2 comprising the amino acid sequence shown as NAK, and LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 47;
HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 1, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 2, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 3, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 4, LCDR2 comprising the amino acid sequence shown as NAK, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 5, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 50
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 51, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 52, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:
53, LCDR2 comprising an amino acid sequence as shown in QMS, LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 54;
v. HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 8, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 9, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 11, LCDR2 comprising the amino acid sequence shown in RAN, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 12, HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 29, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 30, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 31, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:
32, an LCDR1 comprising an amino acid sequence as shown in STS, an LCDR2 comprising an amino acid sequence as shown in SEQ ID No. 33;
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 8, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 9, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 10, LCDR1 comprising the amino acid sequence shown as SEQ ID No. 11, LCDR2 comprising the amino acid sequence shown as RAN, LCDR3 comprising the amino acid sequence shown as SEQ ID No. 12, HCDR1 comprising the amino acid sequence shown as SEQ ID No. 36, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 37, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 38, HCDR3 comprising the amino acid sequence shown as SEQ ID NO:
39, an LCDR1 comprising an amino acid sequence shown as NAK, an LCDR2 comprising an amino acid sequence shown as SEQ ID No. 40, and an LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 8, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 9, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 11, LCDR2 comprising the amino acid sequence shown in RAN, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 12, HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 43, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 44, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 45, and HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 45:
46, LCDR2 comprising an amino acid sequence shown as NAK, LCDR3 comprising an amino acid sequence shown as SEQ ID No. 47;
HCDR1 comprising the amino acid sequence shown in SEQ ID No. 8, HCDR2 comprising the amino acid sequence shown in SEQ ID No. 9, HCDR3 comprising the amino acid sequence shown in SEQ ID No. 10, LCDR1 comprising the amino acid sequence shown in SEQ ID No. 11, LCDR2 comprising the amino acid sequence shown in RAN, LCDR3 comprising the amino acid sequence shown in SEQ ID No. 12, HCDR1 comprising the amino acid sequence shown in SEQ ID No. 50, HCDR2 comprising the amino acid sequence shown in SEQ ID No. 51, HCDR3 comprising the amino acid sequence shown in SEQ ID No. 52, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:
53, LCDR2 comprising an amino acid sequence as shown in QMS, LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 54;
HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 15, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 16, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 17, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 18, LCDR2 comprising the amino acid sequence shown as AAS, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 19
HCDR1 of the amino acid sequence shown as SEQ ID NO. 29, HCDR2 of the amino acid sequence shown as SEQ ID NO. 30, HCDR3 of the amino acid sequence shown as SEQ ID NO. 31, HCDR3 of the amino acid sequence shown as SEQ ID NO:
32, an LCDR1 comprising an amino acid sequence as shown in STS, an LCDR2 comprising an amino acid sequence as shown in SEQ ID No. 33;
x. HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 15, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 16, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 17, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 18, LCDR2 comprising the amino acid sequence shown as AAS, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 19
HCDR1 of the amino acid sequence shown in SEQ ID NO. 36, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 37, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 38, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:
39, an LCDR1 comprising an amino acid sequence shown as NAK, an LCDR2 comprising an amino acid sequence shown as SEQ ID No. 40, and an LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1 comprising the amino acid sequence shown as SEQ ID NO. 15, HCDR2 comprising the amino acid sequence shown as SEQ ID NO. 16, HCDR3 comprising the amino acid sequence shown as SEQ ID NO. 17, LCDR1 comprising the amino acid sequence shown as SEQ ID NO. 18, LCDR2 comprising the amino acid sequence shown as AAS, LCDR3 comprising the amino acid sequence shown as SEQ ID NO. 19
HCDR1 of the amino acid sequence shown as SEQ ID NO. 43, HCDR2 of the amino acid sequence shown as SEQ ID NO. 44, HCDR3 of the amino acid sequence shown as SEQ ID NO. 45:
46, LCDR2 comprising an amino acid sequence shown as NAK, LCDR3 comprising an amino acid sequence shown as SEQ ID No. 47;
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 15, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 16, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 17, LCDR1 comprising the amino acid sequence shown as SEQ ID No. 18, LCDR2 comprising the amino acid sequence shown as AAS, LCDR3 comprising the amino acid sequence shown as SEQ ID No. 19, HCDR1 comprising the amino acid sequence shown as SEQ ID No. 50, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 51, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 52, LCDR1 comprising the amino acid sequence shown as SEQ ID No. 53, LCDR2 comprising the amino acid sequence shown as QMS and LCDR3 comprising the amino acid sequence shown as SEQ ID No. 54.
HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 22, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 23, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 24, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 25, LCDR2 comprising the amino acid sequence shown in AAS, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 26, HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 29, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 30, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 31, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 32, LCDR2 comprising the amino acid sequence shown in STS and LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 33.
HCDR1 comprising the amino acid sequence shown as SEQ ID No. 22, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 23, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 24, LCDR1 comprising the amino acid sequence shown as SEQ ID No. 25, LCDR2 comprising the amino acid sequence shown as AAS, LCDR3 comprising the amino acid sequence shown as SEQ ID No. 26, HCDR1 comprising the amino acid sequence shown as SEQ ID No. 36, HCDR2 comprising the amino acid sequence shown as SEQ ID No. 37, HCDR3 comprising the amino acid sequence shown as SEQ ID No. 38, LCDR1 comprising the amino acid sequence shown as SEQ ID No. 39, LCDR2 comprising the amino acid sequence shown as NAK, and LCDR3 comprising the amino acid sequence shown as SEQ ID No. 40.
xv. comprises an HCDR1 of the amino acid sequence shown in SEQ ID NO. 22, an HCDR2 of the amino acid sequence shown in SEQ ID NO. 23, an HCDR3 of the amino acid sequence shown in SEQ ID NO. 24, an LCDR1 of the amino acid sequence shown in SEQ ID NO. 25, an LCDR2 of the amino acid sequence shown in AAS, an LCDR3 of the amino acid sequence shown in SEQ ID NO. 26, an HCDR1 of the amino acid sequence shown in SEQ ID NO. 43, an HCDR2 of the amino acid sequence shown in SEQ ID NO. 44, an HCDR3 of the amino acid sequence shown in SEQ ID NO. 45:
46, LCDR2 comprising an amino acid sequence shown as NAK, LCDR3 comprising an amino acid sequence shown as SEQ ID No. 47; or (b)
xvi. HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 22, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 23, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 24, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 25, LCDR2 comprising the amino acid sequence shown in AAS, LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 26, HCDR1 comprising the amino acid sequence shown in SEQ ID NO. 50, HCDR2 comprising the amino acid sequence shown in SEQ ID NO. 51, HCDR3 comprising the amino acid sequence shown in SEQ ID NO. 52, LCDR1 comprising the amino acid sequence shown in SEQ ID NO. 53, LCDR2 comprising the amino acid sequence shown in QMS and LCDR3 comprising the amino acid sequence shown in SEQ ID NO. 54.
Conjugate(s)
In some embodiments, an antibody or antigen binding fragment thereof provided herein further comprises one or more conjugate moieties. The conjugate moiety may be linked to an antibody or antigen binding fragment thereof. The binding moiety is a moiety that can be linked to an antibody or antigen binding fragment thereof. It is contemplated that a variety of conjugate moieties may bind to the antibodies or antigen binding fragments thereof provided herein (see, e.g., "conjugate vaccine (Conjugate Vaccines)", "contributions to microbiology and immunology (Contributions to Microbiology and Immunology), j.m.cruse and r.e.lewis, jr. (editors), new York Carger Press (Carger Press, new York), (1989)). These conjugate moieties may be linked to the antibody or antigen-binding fragment thereof by covalent binding (e.g., disulfide bonds), affinity binding, intercalation, coordinate binding, complexation, association, blending, or addition, etc. In some embodiments, the antibody or antigen binding fragment thereof may be linked to one or more conjugates via a linker or cross-linker. The linker or crosslinker comprises a reactive chemical group that can react with an antibody or antigen binding fragment thereof provided herein. The reactive chemical groups may be N-succinimidyl esters and N-sulfosuccinimidyl esters. In addition, the linker includes a reactive chemical group, which may be a dithiopyridyl group that may react with a drug to form a disulfide bond. Linker molecules include, for example, N-succinimidyl 4- (maleimidomethyl) cyclohexanecarboxylate (SMCC), N-succinimidyl 3- (2-pyridyldithio) propionate (SPDP) (see, for example, carlsson et al, J. Biol.Chem.173:723-737 (1978)), N-succinimidyl 4- (2-pyridyldithio) butyrate (SPDB) (see, for example, U.S. Pat. No. 4,563,304), N-succinimidyl 4- (2-pyridyldithio) 2-sulfobutyrate (sulfo-SPDB) (see, for example, U.S. publication No. 2009027413), N-succinimidyl 4- (2-pyridyldithio) valerate (SPP) (see, for example, CAS registry No. 341498-08-6), 2-iminothiolane, or acetyl succinic anhydride. For example, the antibody or cell-binding agent may be modified with a crosslinking reagent, and the resulting antibody or cell-binding agent containing a free or protected thiol group is then reacted with maytansinoid (maytansinoid) containing a disulfide or thiol to produce a conjugate. The conjugate may be purified by chromatography, including but not limited to HPLC, size exclusion, adsorption, ion exchange and affinity capture, dialysis, or tangential flow filtration.
In certain embodiments, the antibodies or antigen binding fragments thereof provided herein may be engineered to contain specific sites other than epitope binding moieties that may be used for binding to one or more conjugate moieties. For example, such sites may include one or more reactive amino acid residues, such as cysteine or histidine residues, to facilitate covalent attachment to the conjugate moiety.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein may be linked to a conjugate moiety, either indirectly or through another conjugate moiety. For example, an antibody or antigen binding fragment thereof provided herein can be conjugated to biotin, followed by indirect conjugation to a second conjugate conjugated to avidin. In some embodiments, the conjugate moiety comprises a scavenging modifier (e.g., a half-life extending polymer such as PEG), a chemotherapeutic agent, a toxin, a radioisotope, a lanthanide, a detectable label (e.g., a luminescent label, a fluorescent label, an enzyme substrate label), a DNA alkylating agent, a topoisomerase inhibitor, a tubulin binding agent, a purification moiety, or other anti-cancer drug (e.g., toll-like receptor 7 (TLR-7), an agonist of TLR-8 and/or TLR-9, an siRNA, an antibody or antigen-binding fragment thereof, a peptide (e.g., a short peptide), etc.).
A "toxin" may be any agent that is harmful to a cell or that can damage or kill a cell. Examples of toxins include, but are not limited to, paclitaxel, CC-1065 and CC-1065 analogs, du Kamei (duocarmycin) and Du Kamei analogs, enediynes such as calicheamicin (calicheamicin), dolastatin (dolastatin) and dolastatin analogs (including auristatin), tolmetin derivatives (tomaymycin derivative), leptomycin derivatives (leptomycin derivative), cisplatin (cislatin), carboplatin (carboplatin), daunorubicin, doxorubicin, vincristine (vincristine), vinblastine (vinblastine), marflange (melphalan), mitomycin C, chlorambucil and morpholino doxorubicin, cytochalasin B ponticin D, ethidium bromide, ipecine, mitomycin, etoposide (etoposide), teniposide (tenoposide), MMAE, MMAF, DM, DM4, vinblastine (vinblastine), colchicine (colchicine), doxorubicin, daunorubicin, dicarboxylanthrone (dihydroxy anthracin dione), mitoxantrone (mitoxantrone), mithramycin (mithramycin), actinomycin D (actinomycin D), 1-dehydrotestosterone, glucocorticoids, procaine (procaine), tetracaine, lidocaine (lidocaine), propranolol (puromycin) and analogs thereof (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine (dacarbazine), alkylating agents (e.g., nitrogen mustard, cetylpiperazine chlorambucil (thioepa chlorambucil), melphalan (melphalan), carmustine (carmustine) (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan (busulfan), dibromomannitol, streptozotocin, mitomycin C and dichlorodiamide platinum (II) (DDP cisplatin), anthracyclines (anthracyclines) (e.g., daunorubicin (daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (dactinomycin) (former actinomycin), bleomycin (bleomycin), mithramycin and Anthramycin (AMC)), antimitotics (e.g., vincristine and vinblastine), topoisomerase inhibitors and tubulin binding agents.
Examples of detectable labels may include fluorescent labels (e.g., fluorescein, rhodamine, dansyl, phycoerythrin, or texas red), enzyme substrate labels (e.g., horseradish peroxidase, alkaline phosphatase, luciferase, glucoamylase, lysozyme, carbohydrate oxidase, or beta-D-galactosidase), radioisotopes (e.g., 123 I、 124 I、 125 I、 131 I、 35 S、 3 H、 111 In、 112 In、 14 C、 64 Cu、 67 Cu、 86 Y、 88 Y、 90 Y、 177 Lu、 211 At、 186 Re、 188 Re、 153 Sm、 212 bi and Bi 32 P, other lanthanoid element), luminescent labels, chromophore moieties, digoxin, biotin/avidin, DNA molecules, or gold for detection.
In certain embodiments, the conjugate moiety may be a scavenging modifier that helps increase the half-life of the antibody. Illustrative examples include water-soluble polymers such as PEG, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, ethylene glycol/propylene glycol copolymers, and the like. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules.
In certain embodiments, the conjugate moiety may be a purification moiety, such as a magnetic bead.
In certain embodiments, the antibodies or antigen-binding fragments thereof provided herein are used as substrates for conjugates.
In certain embodiments, an antibody or antigen binding fragment thereof provided herein is conjugated to a single peptide. Signal peptides (sometimes referred to as signal sequences, leader sequences, or leader peptides) may be used to facilitate secretion and isolation of the antibodies or antigen binding fragments thereof provided herein. Signal peptides are generally characterized as the core of hydrophobic amino acids that are typically cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature protein as it passes through the secretory pathway. Thus, the invention relates to the described polypeptides having a signal sequence and polypeptides (i.e. cleavage products) whose signal sequence has been proteolytically cleaved. In one embodiment, the nucleic acid sequence encoding the signal sequence may be operably linked in an expression vector to a protein of interest, such as a protein that is not normally secreted or otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or simultaneously cleaved. The protein can then be readily purified from the extracellular medium by art-recognized methods. Alternatively, the signal sequence may be linked to the protein of interest using a sequence that facilitates purification, such as using a GST domain.
Chimeric antigen receptor
In certain embodiments, the present disclosure provides a chimeric antigen receptor comprising an antibody or antigen binding fragment thereof provided herein, a transmembrane region, and an intracellular signaling region.
As used herein, the term "chimeric antigen receptor" or "CAR" refers to an engineered receptor that specifically grafts an antigen to a cell (e.g., a T cell, such as a naive T cell, a central memory T cell, an effector memory T cell, a regulatory T cell, a natural killer cell, or any combination thereof). CARs are also known as artificial cell receptors, chimeric cell receptors or chimeric immune receptors. In some embodiments, the CAR comprises an antigen-specific targeting region (e.g., an antigen-binding fragment of an antibody as provided herein), an extracellular region, a transmembrane region, one or more costimulatory regions, and an intracellular signaling region.
In some embodiments, the antigen-specific targeting region is an scFv. In some embodiments, the transmembrane region comprises a transmembrane region of CD3, CD4, CD8 or CD 28. In some embodiments, the costimulatory region comprises the costimulatory domains of CD28, ICOS, CD27, 4-1BB, OX40, and CD 40L. In some embodiments, the intracellular signaling region is selected from the group consisting of: an intracellular signal region sequence of CD3, fcyri, CD27, CD28, CD137, CD134, myD88, CD40, CD278, TLR, or a combination thereof.
The CAR may be transplanted into a variety of cells, for example, allogeneic, autologous, or xenogeneic cells.
The term "allogeneic cells" as used herein refers to any cells derived from different individuals of the same species.
The term "autologous cells" as used herein refers to any cells derived from the same individual that are subsequently reintroduced into the individual.
The term "heterologous cell" as used herein refers to any cell derived from a different individual of a different species.
In certain embodiments, the CAR is transplanted into an immune effector cell, e.g., a T cell, natural killer cell, macrophage, tumor-infiltrating lymphocyte, or the like.
Polynucleotide and recombination method
The present disclosure provides isolated polynucleotides encoding antibodies or antigen binding fragments thereof provided herein or encoding chimeric antigen receptors provided herein. As used herein, the term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single or double stranded form and polymers thereof. Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and/or deoxyinosine residues (see Batzer et al, nucleic acids Ind. 19:5081 (1991); ohtsuka et al, J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al, molecular and cell probing (mol. Cell. Probes), 8:91-98 (1994)).
DNA encoding an antibody or antigen binding fragment thereof or the chimeric antigen receptor provided herein is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of an antibody). The coding DNA may also be obtained by synthetic methods.
Isolated polynucleotides encoding the antibodies or antigen-binding fragments thereof provided herein and/or chimeric antigen receptors provided herein can be inserted into vectors for further cloning (amplification of DNA) or expression using recombinant techniques known in the art. A number of vectors are available. The carrier composition generally includes, but is not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter (e.g., SV40, CMV, EF-1. Alpha.) and a transcription termination sequence.
The present disclosure provides vectors comprising the isolated polynucleotides provided herein. In certain embodiments, a polynucleotide provided herein encodes an antibody or antigen-binding fragment thereof or chimeric antigen receptor, at least one promoter (e.g., SV40, CMV, EF-1 a) operably linked to a nucleic acid sequence, and at least one selectable marker. Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papovaviruses (e.g., SV 40), lambda and M13 phages, plasmids pcDNA3.3, pMD18-T, pOptivec, pCMV, pEGFP, pIRES, pQD-Hyg-Gseu, pALTER, pBAD, pcDNA, pCal, pL, pET, pGEMEX, pGEX, pCI, pEGFT, pSV2, pFUSE, pVITRO, pVIVO, pMAL, pMONO, pSELECT, pUNO, pDUO, psg5L, pBABE, pWPXL, pBI, p15TV-L, pPro18, pTD, pRS10, pLexA, pACT2.2, pCMV-SCRIPT.RTM, pCDM8, pCDNA1.1/amp, pcDNA3.1, pRc/RSV, PCR 2.1, pEF-1, pFB, pSG5, pXT1, pCDEF3, pSVSPORT, pEF-Bos, and the like.
Vectors comprising polynucleotide sequences encoding antibodies or antigen binding fragments thereof or chimeric antigen receptors provided herein can be introduced into host expression systems (e.g., host cells) for cloning or gene expression. In certain embodiments, the host expression systems provided herein are microbial, yeast, or mammalian cells. In certain embodiments, the microorganism is selected from the group consisting of escherichia coli and bacillus subtilis. In certain embodiments, the yeast is a saccharomyces. In certain embodiments, the mammalian cell is selected from the group consisting of: COS, CHO-S, CHO-K1, HEK-293 and 3T3 cells.
Suitable host cells for cloning or expressing the DNA in the vectors herein are the above-described prokaryotic cells, yeast cells, or higher eukaryotic cells. Suitable prokaryotes for this purpose include eubacteria, such as gram-negative or gram-positive organisms, for example Enterobacteriaceae (Enterobacteriaceae), such as Escherichia (e.g. E.coli), enterobacter (Enterobacter), erwinia (Erwinia), klebsiella (Klebsiella), proteus (Proteus), salmonella (Salmonella) (e.g. Salmonella typhimurium (Salmonella typhimurium)), serratia (Serratia) (e.g. Serratia marcescens (Serratia marcescans)) and Shigella (Shigella) and Bacillus (Bacillus) such as Bacillus subtilis and Bacillus licheniformis (B.lichenifermis), pseudomonas (Pseudomonas) such as Pseudomonas aeruginosa (P.augusta) and Streptomyces (Streptomyces).
In addition to prokaryotes, eukaryotic microbes (such as filamentous fungi or yeast) are also suitable cloning or expression hosts for vectors encoding antibodies. Saccharomyces cerevisiae (Saccharomyces cerevisiae) or Saccharomyces cerevisiae are the most commonly used among lower eukaryotic host microorganisms. However, many other genera, species and strains are more common and suitable for use herein, such as schizosaccharomyces pombe (Schizosaccharomyces pombe); kluyveromyces hosts (Kluyveromyces host), such as Kluyveromyces lactis (K.lactis), kluyveromyces fragilis (K.fragilis) (ATCC 12,424), kluyveromyces bulgaricus (K.bulgaricus) (ATCC 16,045), kluyveromyces weissei (K.winkerami) (ATCC 24,178), kluyveromyces (K.waiti) (ATCC 56,500), kluyveromyces drosophila (K.drosophila) (ATCC 36,906), kluyveromyces thermotolerans (K.thermophilus) and Kluyveromyces marxianus (K.marxianus); yarrowia (EP 402,226); pichia pastoris (EP 183,070); candida (Candida); trichoderma reesei (Trichoderma reesia) (EP 244,234); neurospora crassa (Neurospora crassa); schwanniomyces (Schwanniomyces), such as Schwanniomyces western (Schwanniomyces occidentalis); and filamentous fungi (filamentous fungi), such as Neurospora (Neurospora), penicillium (Penicillium), curvularia (Tolypocladium), and Aspergillus hosts (Aspergillus host), such as Aspergillus nidulans (A. Nidulans) and Aspergillus niger (A. Niger).
Suitable host cells for expressing the glycosylated antibodies or antigen-binding fragments thereof provided herein are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. A variety of baculovirus strains and variants have been identified, as well as corresponding permissive insect host cells derived from hosts such as: spodoptera frugiperda (Spodoptera frugiperda) (caterpillars), aedes aegypti (mosquitoes), aedes albopictus (mosquitoes), drosophila melanogaster (Drosophila melanogaster) (drosophila melanogaster), and Bombyx mori (Bombyx mori). A variety of viral strains for transfection are publicly available, for example L-1 variants of the NPV of Spodoptera frugiperda (Autographa californica) and Bm-5 variants of the NPV of Bombyx mori, and such viruses may be used as the viruses herein according to the invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be used as hosts.
However, the most interesting are vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. An example of a useful mammalian host cell line is the monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney (293 or 293 cells subcloned for growth in suspension culture, graham et al, journal of general virology (J.Gen.Virol.)) 36/59 (1977); baby hamster kidney cells (BHK, ATCC CCL 10); chinese hamster ovary cells/-DHFR (CHO, urlaub et al, journal of the national academy of sciences 77:4216 (1980)); mouse Sitertoli cells (TM 4, mather, [ biological reproduction.) ] 23:243-251 (1980) ]; monkey kidney cells (CV 1 ATCC CCL 70); african green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical cancer cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat (buffalo rat) hepatocytes (BRL 3a, atcc CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatocytes (Hep G2, HB 8065); mouse mammary tumor (MMT 060562,ATCC CCL51); TRI cells (Mather et al, "annual book of the New York sciences (Annals N.Y. Acad. Sci.)))" 383:44-68 (1982); MRC 5 cells; FS4 cells; mouse precancerous carcinoma cells (MFC), SNU620 cells, and human hepatoma lines (Hep G2). In some embodiments, the host cell is a mammalian cultured cell line, such as CHO, BHK, NS0, 293, MFC, SNU620, and derivatives thereof.
The host cells are transformed with the expression or cloning vectors described above for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. In another embodiment, the antibodies may be produced by homologous recombination as known in the art. In certain embodiments, the host cell is capable of producing an antibody or antigen-binding fragment thereof provided herein.
The present disclosure also provides a method of expressing an antibody or antigen-binding fragment thereof or chimeric antigen receptor provided herein, comprising culturing a host expression system provided herein under conditions that express the antibody or antigen-binding fragment thereof or chimeric antigen receptor. The host expression systems for producing the antibodies or antigen binding fragments thereof or chimeric antigen receptors provided herein can be cultured in a variety of media. Commercially available media such as Ham's F (Sigma), minimal essential media (Minimal Essential Medium, MEM) (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) are suitable for culturing host cells. In addition, any of the media described below may be used as the medium for the host cells: ham et al, methods of enzymology (meth.Enz.) 58:44 (1979); barnes et al, analytical biochemistry (Anal. Biochem.) 102:255 (1980); U.S. patent No. 4,767,704; 4,657,866; 4,927,762, 4,560,655 or 5,122,469; WO 90/03430; WO 87/00195; or us reissue patent 30,985. Any of these media may be supplemented with hormones and/or other growth factors (e.g., insulin, transferrin or epidermal growth factor), salts (e.g., sodium chloride, calcium, magnesium and phosphate), buffers (e.g., HEPES), nucleotides (e.g., adenosine and thymidine), antibiotics (e.g., GENTAMYCIN) TM Drug), trace elements (defined as inorganic compounds with final concentrations typically in the micromolar range), and glucoseOr an equivalent energy source. Any other necessary supplements may also be included in suitable concentrations known to those skilled in the art. Culture conditions such as temperature, pH, etc., are those previously used with the host cell selected for expression and will be apparent to those skilled in the art.
When recombinant techniques are used, the antibodies may be produced in the cell, in the periplasmic space, or directly secreted into the culture medium. If antibodies are produced intracellularly, as a first step, the host cells or the particulate fragments of the lysed fragments may be removed, for example, by centrifugation or ultrafiltration. Carter et al, bio/technology 10:163-167 (1992) describe a procedure for isolating antibodies secreted into the periplasmic space of E.coli. Briefly, the cell paste was thawed in the presence of sodium acetate (pH 3.5), EDTA and phenylmethylsulfonyl fluoride (PMSF) for about 30 minutes. Cell debris can be removed by centrifugation. When antibodies are secreted into the culture medium, supernatants from such expression systems are typically first concentrated using commercially available protein concentration filters (e.g., amicon or Millipore Pellicon ultrafiltration units). Protease inhibitors such as PMSF may be included in any of the above steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of foreign contaminants.
Antibodies or antigen binding fragments thereof and/or chimeric antigen receptors produced by the host expression system may be purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis, DEAE-cellulose ion exchange chromatography, ammonium sulfate precipitation, salting out, and affinity chromatography, with affinity chromatography being the preferred purification technique.
In certain embodiments, protein a immobilized on a solid phase is used for immunoaffinity purification of antibodies and antigen binding fragments thereof and/or chimeric antigen receptors. Whether protein a is suitable as an affinity ligand depends on the type and isotype of any immunoglobulin Fc domain present in the antibody. Protein A can be used to purify antibodies based on the human gamma 1, gamma 2 or gamma 4 heavy chain (Lindmark et al J.Immunol.62:1-13 (1983)). Protein G is recommended for all mouse isoforms and human gamma 3 (Guss et al, J.European molecular biology journal (EMBO J.)) 5:1567 1575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are also useful. Mechanically stable substrates such as controlled pore glass or poly (styrene divinyl) benzene can achieve faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody includes a CH3 domain, baker bond ABXTM resin (J. T. Baker, phillips burg, N.J.) may be used for purification other techniques for protein purification are also available depending on the antibody to be recovered, such as fractionation on an ion exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSEM, chromatography on anion or cation exchange resins such as polyaspartic acid columns, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation.
After any preliminary purification steps, the mixture comprising the antibody of interest and the contaminant may be subjected to low pH hydrophobic interaction chromatography using an elution buffer having a pH between about 2.5-4.5, preferably at a low salt concentration (e.g., about 0-0.25M salt).
Composition and method for producing the same
The present disclosure further provides compositions comprising an antibody or antigen-binding fragment thereof or chimeric antigen receptor provided by the present disclosure, and one or more carriers.
Carriers for the compositions disclosed herein can include, for example, liquid, gel, or solid carriers, aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, anesthetics, suspending/partitioning agents, sequestering or chelating agents, diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.
Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavouring agents, thickening agents, colouring agents, emulsifying agents or stabilizing agents, such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxyanisole (butylated hydroxanisol), butylated hydroxytoluene, and/or propyl gallate. As disclosed herein, the inclusion of one or more antioxidants, such as methionine, in a composition comprising an antibody or antigen binding fragment and conjugate thereof provided herein reduces oxidation of the antibody or antigen binding fragment thereof. This reduction in oxidation can prevent or reduce loss of binding affinity, thereby improving antibody stability and maximizing shelf life. Thus, in certain embodiments, there is provided a pharmaceutical composition comprising one or more antibodies or antigen binding fragments thereof as disclosed herein and one or more antioxidants such as methionine. Further provided are methods for preventing oxidation, extending shelf life, and/or improving efficacy of an antibody or antigen binding fragment provided herein by mixing the antibody or antigen binding fragment with one or more antioxidants such as methionine.
For further illustration, the carrier may include, for example: aqueous vehicles such as sodium chloride injection, ringer's injection, isotonic dextrose injection, sterile water injection or dextrose and lactate Ringer's injection; nonaqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil or peanut oil; an antimicrobial agent at a bacteria-inhibiting or fungi-inhibiting concentration; isotonic agents, such as sodium chloride or dextrose; buffers, such as phosphate or citrate buffers; antioxidants such as sodium bisulfate; local anesthetics, such as procaine hydrochloride; suspending and dispersing agents, such as sodium carboxymethyl cellulose, hydroxypropyl methylcellulose or polyvinylpyrrolidone; emulsifying agents, such as polysorbate 80 (TWEEN-80); sequestering or chelating agents, such as EDTA (ethylene diamine tetraacetic acid) or EGTA (ethylene glycol tetraacetic acid); ethanol; polyethylene glycol; propylene glycol; sodium hydroxide; hydrochloric acid; citric acid or lactic acid. Antimicrobial agents useful as carriers may be added to the pharmaceutical composition in the multi-dose container, including phenol or cresol, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride, and benzethonium chloride. Suitable excipients may include, for example, water, saline, dextrose, glycerol, or ethanol. Suitable non-toxic auxiliary substances may include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrins.
The composition may be a liquid solution, suspension, emulsion, pill, capsule, tablet, slow release formulation, or powder. Oral formulations may include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinylpyrrolidone, sodium saccharine, cellulose, magnesium carbonate, and the like.
In certain embodiments, the composition is formulated as an injectable composition. The injectable composition may be prepared in any conventional form, such as a liquid solution, suspension, emulsion or solid form suitable for producing a liquid solution, suspension or emulsion. Injectable formulations may include sterile and/or pyrogen-free solutions to be injected, sterile dried soluble products (such as lyophilized powders, including subcutaneous injection tablets) to be combined with solvents prior to use, sterile suspensions to be injected, sterile dried insoluble products to be combined with vehicles prior to use, and sterile and/or pyrogen-free emulsions. The solution may be aqueous or non-aqueous.
In certain embodiments, the unit dose parenteral formulation is packaged in an ampoule, vial or syringe with needle. As is known and practiced in the art, all formulations for parenteral administration should be sterile and pyrogen-free.
In certain embodiments, sterile lyophilized powders are prepared by dissolving an antibody or antigen-binding fragment thereof as disclosed herein in a suitable solvent. The solvent may contain excipients that may improve the stability or other pharmacological components of the powder or reconstituted solution prepared from the powder. Excipients that may be used include, but are not limited to, water, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose or other suitable agents. The solvent may contain a buffer, such as citrate, sodium or potassium phosphate, or other such buffers known to those skilled in the art, which in one embodiment is about neutral pH. The solution is then sterile filtered and then lyophilized under standard conditions known to those skilled in the art to provide the desired formulation. In one embodiment, the resulting solution is dispensed into vials for lyophilization. Each vial may contain a single dose or multiple doses of an antibody or antigen-binding fragment thereof or a combination thereof. Overfilling the vial with an amount slightly higher than that required for each dose or doses (e.g., about 10%) is acceptable in order to facilitate accurate sampling and accurate dosing. The lyophilized powder may be stored under suitable conditions (e.g., at about 4 ℃ to room temperature).
The lyophilized powder is reconstituted with water for injection to provide a formulation for parenteral administration. In one embodiment, sterile and/or pyrogen-free water or other suitable liquid carrier is added to the lyophilized powder for reconstitution. The exact amount depends on the selected therapy administered and can be determined empirically.
Kit for detecting a substance in a sample
In certain embodiments, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof provided herein and/or a composition provided herein and/or a chimeric antigen receptor provided herein. In certain embodiments, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof provided herein and/or a composition provided herein and/or a chimeric antigen receptor provided herein and a second agent. In certain embodiments, the second agent is selected from the group consisting of: detection agents, chemotherapeutic agents, anti-cancer drugs, radiation therapies, immunotherapeutic agents, anti-angiogenic agents, targeted therapies, cell therapies, gene therapies, hormonal therapies, antiviral agents, antibiotics, analgesics, antioxidants, metal chelators, and cytokines.
In certain embodiments, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof and/or chimeric antigen receptor and/or composition provided herein for detecting an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in a sample. In some embodiments, the bispecific PD-L1/4-1BB antibody is ATG-101.
In certain embodiments, the present disclosure provides a kit comprising an antibody or antigen-binding fragment thereof and/or chimeric antigen receptor and/or composition provided herein for detecting an anti-drug antibody (ADA) to an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody.
As used herein, "anti-drug antibody" or "ADA" refers to an antibody that specifically binds to any portion of a drug. For example, an anti-drug antibody may be an antibody or fragment thereof, which may be directed against any region of an antibody drug, such as the variable domain, constant domain, or sugar structure of an antibody. Such anti-drug antibodies may appear as immunogenic responses to the patient during drug therapy. ADA can be any one of the immunoglobulin isotypes (e.g., igM, igE, igA, igG, igD) or subclasses of IgG (IgG 1, 2, 3, and 4). ADA includes ADA from any animal source, including, for example, human or non-human animal (e.g., veterinary) sources.
As will be apparent to those of skill in the art, such kits may further include one or more of a variety of conventional kit components, such as containers with one or more carriers, additional containers, and the like, if desired. Instructions (as an insert or as a label) indicating the amount of the component to be administered, instructions for administration, and/or instructions for mixing the components may also be included in the kit.
Method and use
The present disclosure also provides methods of detecting the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in a sample, comprising contacting the sample with an antibody or antigen-binding fragment thereof and/or a composition and/or chimeric antigen receptor provided herein and determining the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in the sample. In some embodiments, the method is a non-diagnostic method. In some embodiments, the methods are used in pharmacokinetic, drug resistance or neutralization assays for anti-PD-L1 antibodies, anti-4-1 BB antibodies, or bispecific PD-L1/4-1BB antibodies.
The present disclosure also provides a method of reducing side effects caused by administration of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody to a subject, the method comprising administering to the subject an antibody of the present disclosure, or an antigen-binding fragment thereof, and/or a composition and/or chimeric antigen receptor. In some embodiments, the side effect is a cytokine storm.
A "cytokine storm", also known as Cytokine Release Syndrome (CRS), is a condition that occurs when the immune system of a subject responds too strongly to infection or immunotherapy. In some embodiments, the cytokine storm is caused by administration of ATG-101 to a subject. Cytokine levels can be monitored by detecting the protein level of the cytokine in a biological sample from the subject. Cytokine levels can also be monitored by detecting nucleic acid levels of cytokines in a biological sample from a subject. In some embodiments, the cytokine is selected from the group consisting of: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IL-1Ra, IL-2R, IFN- α, IFN- γ, MIP-1α, mcPi-1β, MCP-1, TNF α, GM-CSF, G-CSF, CXCL9, CXCL10, CXCR factor, VEGF, RANTES, earthThe gamma ΓN, EGF, HGF, FGF- β, CD40L, ferritin, and any combination thereof.
In some embodiments, the anti-PD-L1 antibody, the anti-4-1 BB antibody, or the bispecific PD-L1/4-1BB antibody is administered to the subject to prevent or treat a disease, disorder, or condition associated with PD-L1 and/or 4-1 BB. In certain embodiments, the subject is a human.
In some embodiments, the PD-L1 and/or 4-1 BB-related disease, disorder, or condition is characterized by the expression or overexpression of PD-L1 and/or 4-1BB.
In certain embodiments, the PD-L1 and/or 4-1BB related disease, disorder or condition is cancer. In certain embodiments, the cancer is a PD-L1 and/or 4-1BB expressing cancer. As used herein, "PD-L1 and/or 4-1BB expressing cancer" refers to a cancer characterized by expressing PD-L1 and/or 4-1BB protein in cancer cells (i.e., tumor-infiltrating immune cells) or by expressing PD-L1 and/or 4-1BB in cancer cells (i.e., tumor-infiltrating immune cells) at a level that is significantly higher than the level expected for normal cells. Various methods can be used to determine the presence and/or amount of PD-L1 and/or 4-1BB in a test biological sample of a subject. For example, a test biological sample may be exposed to an anti-PD-L1 and/or 4-1BB antibody or antigen-binding fragment thereof, which binds and detects the expressed PD-L1 and/or 4-1BB protein. Alternatively, PD-L1 and/or 4-1BB may also be detected at the nucleic acid expression level using methods such as qPCR, reverse transcriptase PCR, microarray, SAGE, FISH, and the like. In some embodiments, the test sample is derived from a cancer cell or tissue, or a tumor infiltrating immune cell. The reference sample may be a control sample obtained from a healthy or non-diseased individual, or a healthy or non-diseased sample obtained from the same individual from which the test sample was obtained. For example, the reference sample may be a non-diseased sample adjacent to or in the vicinity of the test sample (e.g., a tumor). In certain embodiments, the cancer is a solid tumor or hematological tumor.
In certain embodiments, the PD-L1 and/or 4-1BB related disease, disorder, or condition is selected from the group consisting of: lung cancer (e.g., non-small cell lung cancer (NSCLC), small Cell Lung Cancer (SCLC) (lung adenocarcinoma or lung squamous cell carcinoma), peritoneal cancer, carcinoid, bone cancer, pancreatic cancer, primitive neuroectodermal tumors, skin cancer, gall bladder cancer, head and neck cancer, squamous cell cancer, uterine cancer, ovarian cancer, rectal cancer, prostate cancer, bladder cancer (e.g., urothelial cancer), anal region cancer (e.g., anal squamous cell cancer), gastric cancer (gastric or stomach cancer) (e.g., gastrointestinal cancer), esophageal cancer, colon cancer, breast cancer, uterine cancer, liver cancer (e.g., hepatoblastoma, hepatocellular carcinoma/hepatoma or liver cancer), cholangiocarcinoma, sarcoma, colorectal cancer, fallopian tube cancer, salivary gland cancer, cervical cancer, endometrial or uterine cancer, osteosarcoma, vaginal cancer, vulval cancer, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, nasopharyngeal cancer, soft tissue sarcoma, polycythemia vera, real world cancer, penile cancer, kidney or urinary tract cancer (e.g., renal rhabdoid tumor), cutaneous T-cell lymphoma, medulloblastoma, nephroblastoma, myelodysplastic syndrome, chronic and non-chronic myeloproliferative disorders, chorioallantoic papilloma, renal cell carcinoma, renal pelvis carcinoma, central Nervous System (CNS) neoplasms, soft tissue sarcomas (e.g., rhabdomyosarcoma, fibrosarcoma, kaposi's sarcoma), spinal cord shaft tumors, gliomas (e.g., ependymoma, astrocytoma, anaplastic astrocytoma, oligodendrogliomas), eye cancers (e.g., retinoblastoma), brain stem glioma, or mixed glioma such as oligodendroglioma, brain tumor (e.g., glioblastoma/glioblastoma multiforme (GBM), non-glioblastoma brain tumor or meningioma), melanoma (e.g., cutaneous or intraocular melanoma), thrombocytosis, mesothelioma, mycosis fungoides, szezali syndrome, primary myelofibrosis, solitary plasmacytome, vestibular schwannoma, ewing's sarcoma, chondrosarcoma, MYH-related polyposis, pituitary adenoma, pediatric cancers such as pediatric sarcoma (e.g., neuroblastoma, rhabdomyosarcoma and osteosarcoma), hematologic cancers, hodgkin's lymphoma, non-hodgkin's lymphoma, leukemia (e.g., lymphoblastic/lymphoblastic leukemia), chronic or acute leukemia, mast cell leukemia, lymphocytic lymphoma, primary CNS lymphoma, chronic Lymphocytic Leukemia (CLL), acute Lymphocytic Leukemia (ALL), chronic Myelogenous Leukemia (CML), myelogenous leukemia (cmm), multiple myeloma (dysmyelomas, lymphoblastic leukemia (mcbl), multiple myeloma (lymphomas, lymphomas (dysleukemia), multiple myeloma, lymphomas (lymphomas), or lymphomas (lymphomas), leukemia-relapses) (one of one or multiple myeloma Diffuse large B-cell lymphoma (DLBCL), DLBCL caused by follicular lymphoma, advanced B-cell lymphoma, primary mediastinum large B-cell lymphoma, follicular Lymphoma (FL), and primary mediastinum B-cell lymphoma.
In some embodiments, the subject has been identified as having cancer cells or tumor infiltrating immune cells that express PD-L1 and/or 4-1BB, optionally at a level significantly higher than that typically found on non-cancer cells.
In some embodiments, the antibodies or antigen binding fragments thereof and/or compositions and/or chimeric antigen receptors provided herein are used to neutralize an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody (e.g., ATG-101).
The amount of antibody or antigen binding fragment provided herein will depend on various factors known in the art, such as, for example, body weight, age, prior medical history, current drug treatment, potential for health and cross-reactivity of the subject, allergies, sensitivity and adverse side effects, and the route of administration and the extent of disease progression. Those skilled in the art (e.g., a physician or veterinarian) can scale down or up the dosage according to these and other circumstances or instructions.
In certain embodiments, the antibodies or antigen binding fragments and/or chimeric receptors provided herein can be administered at a dose of about 0.01mg/kg to about 100 mg/kg. In certain embodiments, the dosage administered may vary during the course of treatment. For example, in certain embodiments, the initial administered dose may be higher than the subsequent administered dose. In certain embodiments, the dosage administered may vary during the course of treatment according to the subject's response.
The dosage regimen can be adjusted to provide the best desired response (e.g., therapeutic response). For example, a single dose may be administered, or multiple separate doses may be administered over time.
The antibodies or antigen-binding fragments thereof and/or chimeric antigen receptors provided herein can be administered by any route known in the art, for example, by parenteral routes including subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, or intradermal injection; or by a non-parenteral route including transdermal, oral, intranasal, intraocular, sublingual, rectal or topical administration.
In some embodiments, an antibody or antigen binding fragment thereof and/or chimeric antigen receptor provided herein can be administered alone or in combination with a therapeutically effective amount of a second agent. For example, the antibodies or antigen binding fragments thereof and/or chimeric antigen receptors disclosed herein can be administered in combination with a second agent, e.g., a detection agent, a chemotherapeutic agent, an anticancer drug, a radiotherapeutic agent, an immunotherapeutic agent, a targeted therapeutic agent, a cell therapy agent, a gene therapy agent, a hormone therapy agent, an antiviral agent, an antibiotic, an analgesic, an antioxidant, a metal chelator, a cytokine, an active agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulatory molecule agonist, a co-inhibitory molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, a detectable label or reporter, an antibacterial agent, a gene editor, a beta agonist, a viral RNA inhibitor, a polymerase inhibitor, an interferon, or a microrna.
As used herein, the term "immunotherapy" refers to a type of therapy that stimulates the immune system against diseases such as cancer or enhances the immune system in a general manner. Examples of immunotherapy include, but are not limited to, checkpoint modulators, adoptive cell transfer, cytokines, oncolytic viruses, and therapeutic vaccines.
"targeted therapies" are the types of therapies that act on specific molecules associated with cancer, such as specific proteins that are present in cancer cells but not in normal cells or are more abundant in cancer cells, or target molecules in the cancer microenvironment that contribute to cancer growth and survival. Targeted therapies target therapeutic agents to tumors, thereby protecting normal tissue from the therapeutic agent.
In certain of these embodiments, the antibody or antigen-binding fragment thereof provided herein and/or the composition provided herein and/or the chimeric antigen receptor provided herein is administered in combination with one or more additional agents, may be administered concurrently with one or more additional therapeutic agents, and in certain of these embodiments, the antibody or antigen-binding fragment thereof and/or the composition provided herein and/or the chimeric antigen receptor provided herein and additional agents may be administered as part of the same composition. However, administration of an antibody or antigen binding fragment thereof and/or a composition provided herein and/or a chimeric antigen receptor provided herein in "combination" with another agent need not be administered simultaneously with or in the same composition as the agent. An antibody or antigen-binding fragment, composition or chimeric antigen receptor thereof administered before or after another agent is considered to be administered "in combination" with the agent, as the phrase is used herein, even if the antibody or antigen-binding fragment, composition or chimeric antigen receptor and the second agent are administered by different routes. Where possible, additional agents administered in combination with the antibodies or antigen binding fragments, compositions or chimeric antigen receptors disclosed herein are administered according to the schedules listed in the product information sheet of additional therapeutic agents or according to physician's Desk Reference manual 2003 (Physicians' Desk Reference), 57 th edition, medical economics company (Medical Economics Company); ISBN:1563634457, 57 th edition (11 2002), or protocols well known in the art.
In another aspect, the present disclosure provides a kit provided herein comprising an antibody or antigen-binding fragment thereof provided herein and/or a composition provided herein and/or a chimeric antigen receptor provided herein, optionally conjugated to a detectable moiety, which can be used to detect ATG-101. The kit may further comprise instructions for use.
In another aspect, the disclosure also provides a use of an antibody provided herein or an antigen-binding fragment thereof and/or a composition provided herein and/or a chimeric antigen receptor provided herein in the preparation of a kit, wherein the kit is used in a method for detecting an anti-drug antibody (ADA) (e.g., ATG-101) of an anti-PD-L1 antibody, an anti-4-1 BB antibody or a bispecific PD-L1/4-1BB antibody.
In some embodiments, the antibodies or antigen-binding fragments thereof used in the methods, kits, or uses as described above include a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof. In some embodiments, the first antibody or antigen binding fragment thereof comprises:
i. one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: SEQ ID NOS 6, 13, 20 and 27; and
One or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.7, 14, 21 and 28.
In some embodiments, the first antibody or antigen binding fragment thereof comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 1, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 2, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 3, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 4, said LCDR1 comprising an amino acid sequence as shown in NAK, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 5;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID No. 8, said HCDR2 comprising an amino acid sequence as shown in SEQ ID No. 9, said HCDR3 comprising an amino acid sequence as shown in SEQ ID No. 10, said LCDR1 comprising an amino acid sequence as shown in SEQ ID No. 11, said LCDR2 comprising an amino acid sequence as shown in RAN, said LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 12;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 15, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 16, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 17, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 18, said LCDR2 comprising an amino acid sequence shown as AAS, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 19; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 22, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 23, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 24, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 25, said LCDR2 comprising an amino acid sequence as shown in AAS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 26.
In some embodiments, the second antibody or antigen binding fragment thereof comprises:
i. one or two or three heavy chain complementarity determining regions (HCDR 1, HCDR2 and/or HCDR 3) comprised within any one of the heavy chain Variable (VH) region sequences selected from the group consisting of: 34, 41, 48 and 55; and
One or two or three light chain complementarity determining regions (LCDR 1, LCDR2 and/or LCDR 3) comprised within any one of the light chain Variable (VL) region sequences selected from the group consisting of: SEQ ID NOS.35, 42, 49 and 56.
In some embodiments, the second antibody or antigen binding fragment thereof comprises:
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 29, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 30, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 31, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 32, said LCDR2 comprising an amino acid sequence as shown in STS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 33;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 36, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 37, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 38, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 39, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 40;
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence shown as SEQ ID No. 43, said HCDR2 comprising an amino acid sequence shown as SEQ ID No. 44, said HCDR3 comprising an amino acid sequence shown as SEQ ID No. 45, said LCDR1 comprising an amino acid sequence shown as SEQ ID No. 46, said LCDR2 comprising an amino acid sequence shown as NAK, said LCDR3 comprising an amino acid sequence shown as SEQ ID No. 47; or (b)
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 50, said HCDR2 comprising an amino acid sequence as shown in SEQ ID NO. 51, said HCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 52, said LCDR1 comprising an amino acid sequence as shown in SEQ ID NO. 53, said LCDR2 comprising an amino acid sequence as shown in QMS, said LCDR3 comprising an amino acid sequence as shown in SEQ ID NO. 54.
In some embodiments, the sample used in the method, kit or use as described above is selected from the group consisting of: tissue sections, biopsies, paraffin embedded tissue, body fluids, colonic exudates, surgical resection samples, isolated blood cells, cells isolated from blood, and any combination thereof. In some embodiments, the bodily fluid is selected from the group consisting of: whole blood, serum, plasma, urine, mucus, saliva, peritoneal fluid, pleural fluid, synovial fluid, cerebrospinal fluid, pleural effusion, peritoneal effusion, and any combination thereof.
In some embodiments, the bispecific PD-L1/4-1BB antibody used in the methods, kits, or uses as described above is ATG-101.
The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. All of the specific compositions, materials, and methods described below fall within the scope of the invention, in whole or in part. These specific compositions, materials, and methods are not intended to limit the invention but are merely illustrative of specific embodiments that fall within the scope of the invention. Those skilled in the art can develop equivalent compositions, materials and methods without utilizing the inventive capabilities and without departing from the scope of the present invention. It will be appreciated that many variations may be made in the procedure described herein while still remaining within the scope of the invention. It is the intention of the inventors of the present invention that such variations are included within the scope of the invention.
Examples
Example 1 antibody production
1.1Immunization
To generate antibodies against the PD-L1 binding portion and the 4-1BB binding portion of ATG-101, SJL mice were immunized with two immunogenic peptides: YN-035 (described in WO2019196309A1, the entire contents of which are incorporated herein by reference) F (ab') 2 And scF targeting 4-1BB V -Fc. F (ab') 2 Is produced by pepsin digestion of parent antibody YN-035, which provides the PD-L1 binding portion of ATG-101 (pepsin: YN-035 ratio 1:4, reacted overnight at 37 ℃) and by ligating the 4-1BB binding portion of ATG-101 (i.e., the 4-1BB specific scFv domain) with the N-terminus of human IgG1 Fc to produce scFv-Fc targeting 4-1 BB. The primary immunization is followed by several booster immunizations until the animals develop satisfactory antiserum titers suitable for hybridoma development. Gerbu MM was used as an immunoadjuvant. The groupings of animals are shown in table 5 below. Immunization protocols for the two groups of animals are shown in table 6 below.
TABLE 5 grouping of animals
Group of | Immunogens | Pathway | Animal/strain | Group size | Dosage of |
1 | PD-L1-targeted YN-035F (ab') 2 | Tar joint | SJL | 5/5 | 10 μg per mouse |
2 | 4-1 BB-targeted scFv-Fc | Tar joint | SJL | 5/5 | 10 μg per mouse |
TABLE 6 immunization protocols for groups 1 and 2
1.2 hybridoma Generation and screening
Hybridomas are produced by fusing myeloma with spleen cells of mice assessed by a test blood collection ELISA for the PD-L1 binding portion or 4-1BB binding portion of ATG-101, as determined to be the mice with the best immune response. Lymphocytes from spleen and lymph nodes were fused with Sp2/0-Ag14 cell line using an optimized electrofusion protocol. Multiple fusions are performed to ensure success of the project.
The fusion cells were seeded (1X 10 per well) 4 To 10 5 Individual cells) into a stack of 96-well plates. The growth of cells in the plates was monitored and fed once a week. At 10-1Wells with cell growth within 4 days will be picked by ELISA experiments through primary screening. For group 1, F (ab') from the primary screening pair with YN-035 2 Positive parent clones positive for human IgG1 and negative for binding were amplified into 24 well plates and subjected to secondary screening. For group 2, positive parental clones from the primary screening that were positive for binding to scFv-Fc targeting 4-1BB and negative for human IgG1 were amplified into 24-well plates and secondary screened.
After the primary screening, a secondary screening was performed, again by ELISA screening to amplify positive parental clones in 24-well plates. For group 1, F (ab') of pair and YN-035 was selected 2 Positive parental clones positive for ATG-101 binding and negative for human IgG1 were subcloned. For group 2, positive parental clones positive for binding to scFv-Fc, ATG-101 targeting 41BB and negative for human IgG1 were selected for subcloning. Two groups were also subjected to a competition ELISA to assess the blocking ability of antibodies produced by the hybridoma candidates for inhibition of ATG-101 binding to PD-L1 or 4-1BB, including both competitive and non-competitive clones.
Parent hybridomas having the desired reactivity and isotype from the above-described screening funnel are then subcloned by multiple rounds of limiting dilution or single cell sorting until a monoclonal is obtained.
Cells in subclones plates were screened by ELISA as described in the secondary screen, and subclones with good binding capacity were expanded to 24 wells for confirmation testing.
The desired subcloned cell lines were sequenced and further expanded into culture flasks for cryopreservation. Initially at 0.5-1.0X10 7 Individual cells/vials 4-6 vials per cell line were cryopreserved. If desired, a master cell bank and a working cell bank are established for the selected most valuable cell line.
As a result, 8 antibodies having unique sequences were found, which were positive for binding to YN-035 (PD-L1) and ATG-101, or to scFv-Fc targeting 4-1BB and ATG-101, and negative for binding to human IgG1 (as shown in tables 7A and 7B below), indicating that these antibodies specifically recognized the antigen-targeting region of ATG-101.
TABLE 7A binding affinity of selected antibodies to ATG-101 and their ability to compete with ATG-101 for binding to PD-L1 (OD 450 Value of
TABLE 7 binding affinity of selected antibodies to ATG-101 and their competitive capacity (OD) 450 Value of
Example 2 characterization of antibodies
2.1 antibodies
Hybridoma antibody clones 10F10G7, 9D6E11, 27E8A8, 31B6G8, 50D6E10, 58H6F8, 63C9C12 and 75H9F7 were characterized and their sequences were identified by the following methods.
2.2 hybridoma sequencing
Total RNA was isolated from hybridoma cells according to the technical manual of RNAiso Plus (TAKARA catalog number 9109). The total RNA was then reverse transcribed into cDNA using isotype specific antisense primers or universal primers according to the technical manual of PrimeScript II strand 1 cDNA synthesis kit (TAKARA catalog number 6210A). According to TaKaRa Taq TM (catalog number R001A) antibody fragments of VH and VL were amplified. The amplified antibody fragments were cloned individually into standard cloning vectors. Colony PCR was performed to screen clones with inserts of the correct size. Not less than five colonies of inserts of the correct size per fragment were sequenced. The sequences of the different clones were aligned and consensus sequences of these clones were provided.
The variable region sequences of the hybridoma antibodies are provided in table 4 above.
2.3 ELISA binding affinity
The binding affinity of the antibodies to ATG-101 was determined by ELISA.
Cell culture plates were coated with 100. Mu.l/well of 1. Mu.g/ml antigen (ATG-101, fully human IgG) and incubated for 2 hours at 37℃with sealing.
Wash the plate 3 times with a knockout.
Plates were incubated with 300 μl of blocking buffer per well for 2 hours at 37 ℃.
Titration of antibodies by serial dilution, the titrated antibodies will be used for incubation. The solution was prepared by dilution with buffer to achieve final concentration: 10-fold dilutions were performed consecutively, from 100nM (at 8 spots), and incubation with 100. Mu.l/well solution was continued for 1 hour at 37 ℃.
Wash the plate 3 times with a knockout. Secondary antibody (100. Mu.l/well, anti-mouse IgG-HRP at 1:10000 dilution) was added and incubated for 0.5 hours at 37 ℃.
Wash the plate 6 times with a dispenser. 100 μl/well TMB working solution (prepared by mixing solutions A and B at a 1:1 ratio) was added and incubated for 15 minutes at 37deg.C. The reaction was quenched by the addition of 50. Mu.l/well 1N HCl.
The absorbance of each well was read by a microplate reader at a wavelength of 450 nm. Data were analyzed by GraphPad Prism and plotted.
The results are shown in fig. 1A to 1F. As shown in fig. 1A to 1F, selected antibody clones 10F10G7, 9D6E11, 27E8A8, 31B6G8, 50D6E10, 58H6F8, 63C9C12 and 75H9F7 specifically bound to ATG-101, but not IgG1 from negative control mice.
2.4 characterization of antibody Capacity
Antibody competence against ATG-101 and the corresponding antigen was determined by ELISA.
Cell culture plates were coated with 100. Mu.L/well antigen (1. Mu.g/mL PD-L1 or 4-1 BB) and incubated overnight at 4 ℃.
Wash plates 3 times with PBST buffer.
Blocking with a PBST buffer plate pair containing 1% BSA at 37℃for 2 hours.
Wash plates 3 times with PBST buffer.
Add 100. Mu.L/well primary antibody (ATG-101 0.2 nM) and test antibody (100 nm,1:10 serial dilutions, 8 dilution gradients) and incubate at 37℃for 1.5 hours.
Wash plates 3 times with PBST buffer.
mu.L/well secondary antibody (anti-human IgG-HRP) was added and incubated for 1 hour at 37 ℃.
Plates were washed 5 times with PBST buffer and then 100 μl/well TMB was added and incubated for 10 minutes.
Stop the reaction with 50. Mu.L/well 1N HCl.
Absorbance was read with a microplate reader (Molecular device spectra max plus 384) at a wavelength of 450 nm.
The results are shown in fig. 2, table 8A and table 8B below. As shown in fig. 2, table 8A and table 8B, selected antibody clones 10F10G7, 9D6E11, 27E8A8 and 31B6G8 showed different competence for ATG-101 binding to human PD-L1 protein; and selected antibody clones 50D6E10, 58H6F8, 63C9C12 and 75H9F7 showed different competence for ATG-101 binding to human 4-1BB protein.
TABLE 8A binding affinity of selected antibodies to ATG-101 and competitor ability to ATG-101 to bind PD-L1
/>
TABLE 8 binding affinity of selected antibodies to ATG-101 and competitor ability to ATG-101 to bind 4-1BB
/>
Claims (39)
1. An anti-drug antibody against a PD-L1/4-1BB bispecific antibody comprising:
i. heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 1, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 2, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 3, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 4, the amino acid sequence of LCDR2 is shown in NAK, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 5;
heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 8, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 9, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 10, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 11, the amino acid sequence of LCDR2 is shown in RAN, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 12;
Heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 16, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 17, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 18, the amino acid sequence of LCDR2 is shown in AAS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 19;
heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 22, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 23, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 24, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 25, the amino acid sequence of LCDR2 is shown in AAS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 26;
v. heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 29, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 30, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 31, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 32, the amino acid sequence of LCDR2 is shown in STS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 33;
Heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO:36, the amino acid sequence of HCDR2 is shown as SEQ ID NO:37, the amino acid sequence of HCDR3 is shown as SEQ ID NO:38, the amino acid sequence of LCDR1 is shown as SEQ ID NO:39, the amino acid sequence of LCDR2 is shown as NAK, and the amino acid sequence of LCDR3 is shown as SEQ ID NO: 40;
heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO. 43, the amino acid sequence of HCDR2 is shown as SEQ ID NO. 44, the amino acid sequence of HCDR3 is shown as SEQ ID NO. 45, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 46, the amino acid sequence of LCDR2 is shown as NAK, and the amino acid sequence of LCDR3 is shown as SEQ ID NO. 47; or (b)
Heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO. 50, the amino acid sequence of HCDR2 is shown as SEQ ID NO. 51, the amino acid sequence of HCDR3 is shown as SEQ ID NO. 52, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 53, the amino acid sequence of LCDR2 is shown as QMS, and the amino acid sequence of LCDR3 is shown as SEQ ID NO. 54.
2. The anti-drug antibody of claim 1, comprising a heavy chain Variable (VH) region and a light chain Variable (VL) region amino acid sequence pair selected from the group consisting of: SEQ ID NOS 6 and 7, 13 and 14, 20 and 21, 27 and 28, 34 and 35, 41 and 42, 48 and 49, and 55 and 56.
3. The anti-drug antibody of claim 1 or 2, which is capable of specifically binding to the PD-L1 binding portion and/or the 4-1BB binding portion of ATG-101; or compete with ATG-101 for binding to PD-L1 and/or 4-1BB.
4. The anti-drug antibody of claim 1 or 2, which is a chimeric or humanized antibody.
5. The anti-drug antibody of claim 1 or 2, which is a labeled antibody, a bivalent antibody, an anti-idiotype antibody or a fusion protein.
6. The anti-drug antibody according to claim 1 or 2, which is Fab, fab ', F (ab') 2 Fv fragments, or single chain antibody molecules (scFv).
7. The anti-drug antibody of claim 1 or 2, further comprising an Fc region.
8. The anti-drug antibody of claim 7, further comprising an Fc region of human IgG.
9. The anti-drug antibody of claim 8, wherein the Fc region is derived from human IgG1, igG2, igG3, or IgG4.
10. The anti-drug antibody of claim 9, wherein the Fc region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 75-78.
11. The anti-drug antibody of claim 1 or 2, wherein the light chain is a lambda light chain or a kappa light chain.
12. The anti-drug antibody of claim 1, which is a bispecific or multispecific antibody.
13. The anti-drug antibody of claim 12, capable of specifically binding to the PD-L1 binding portion and the 4-1BB binding portion of ATG-101.
14. The anti-drug antibody of claim 13, comprising:
i. HCDR1 of the amino acid sequence shown in SEQ ID NO. 1, HCDR2 of the amino acid sequence shown in SEQ ID NO. 2, HCDR3 of the amino acid sequence shown in SEQ ID NO. 3, LCDR1 of the amino acid sequence shown in SEQ ID NO. 4, LCDR2 of the amino acid sequence shown in NAK and LCDR3 of the amino acid sequence shown in SEQ ID NO. 5; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 29, HCDR2 of the amino acid sequence shown as SEQ ID NO. 30, HCDR3 of the amino acid sequence shown as SEQ ID NO. 31, LCDR1 of the amino acid sequence shown as SEQ ID NO. 32, LCDR2 of the amino acid sequence shown as STS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 33;
HCDR1 of the amino acid sequence shown as SEQ ID No. 1, HCDR2 of the amino acid sequence shown as SEQ ID No. 2, HCDR3 of the amino acid sequence shown as SEQ ID No. 3, LCDR1 of the amino acid sequence shown as SEQ ID No. 4, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID No. 5; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 36, HCDR2 of the amino acid sequence shown as SEQ ID NO. 37, HCDR3 of the amino acid sequence shown as SEQ ID NO. 38, LCDR1 of the amino acid sequence shown as SEQ ID NO. 39, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 40;
HCDR1 of the amino acid sequence shown as SEQ ID No. 1, HCDR2 of the amino acid sequence shown as SEQ ID No. 2, HCDR3 of the amino acid sequence shown as SEQ ID No. 3, LCDR1 of the amino acid sequence shown as SEQ ID No. 4, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID No. 5; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 43, HCDR2 of the amino acid sequence shown as SEQ ID NO. 44, HCDR3 of the amino acid sequence shown as SEQ ID NO. 45, LCDR1 of the amino acid sequence shown as SEQ ID NO. 46, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 47;
HCDR1 of the amino acid sequence shown as SEQ ID No. 1, HCDR2 of the amino acid sequence shown as SEQ ID No. 2, HCDR3 of the amino acid sequence shown as SEQ ID No. 3, LCDR1 of the amino acid sequence shown as SEQ ID No. 4, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID No. 5; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 50, HCDR2 of the amino acid sequence shown as SEQ ID NO. 51, HCDR3 of the amino acid sequence shown as SEQ ID NO. 52, LCDR1 of the amino acid sequence shown as SEQ ID NO. 53, LCDR2 of the amino acid sequence shown as QMS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 54;
v. HCDR1 of the amino acid sequence shown in SEQ ID NO. 8, HCDR2 of the amino acid sequence shown in SEQ ID NO. 9, HCDR3 of the amino acid sequence shown in SEQ ID NO. 10, LCDR1 of the amino acid sequence shown in SEQ ID NO. 11, LCDR2 of the amino acid sequence shown in RAN and LCDR3 of the amino acid sequence shown in SEQ ID NO. 12; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 29, HCDR2 of the amino acid sequence shown as SEQ ID NO. 30, HCDR3 of the amino acid sequence shown as SEQ ID NO. 31, LCDR1 of the amino acid sequence shown as SEQ ID NO. 32, LCDR2 of the amino acid sequence shown as STS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 33;
HCDR1 of the amino acid sequence shown in SEQ ID NO. 8, HCDR2 of the amino acid sequence shown in SEQ ID NO. 9, HCDR3 of the amino acid sequence shown in SEQ ID NO. 10, LCDR1 of the amino acid sequence shown in SEQ ID NO. 11, LCDR2 of the amino acid sequence shown in RAN and LCDR3 of the amino acid sequence shown in SEQ ID NO. 12; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 36, HCDR2 of the amino acid sequence shown as SEQ ID NO. 37, HCDR3 of the amino acid sequence shown as SEQ ID NO. 38, LCDR1 of the amino acid sequence shown as SEQ ID NO. 39, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 40;
HCDR1 of the amino acid sequence shown in SEQ ID NO. 8, HCDR2 of the amino acid sequence shown in SEQ ID NO. 9, HCDR3 of the amino acid sequence shown in SEQ ID NO. 10, LCDR1 of the amino acid sequence shown in SEQ ID NO. 11, LCDR2 of the amino acid sequence shown in RAN and LCDR3 of the amino acid sequence shown in SEQ ID NO. 12; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 43, HCDR2 of the amino acid sequence shown as SEQ ID NO. 44, HCDR3 of the amino acid sequence shown as SEQ ID NO. 45, LCDR1 of the amino acid sequence shown as SEQ ID NO. 46, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 47;
HCDR1 of the amino acid sequence shown as SEQ ID No. 8, HCDR2 of the amino acid sequence shown as SEQ ID No. 9, HCDR3 of the amino acid sequence shown as SEQ ID No. 10, LCDR1 of the amino acid sequence shown as SEQ ID No. 11, LCDR2 of the amino acid sequence shown as RAN and LCDR3 of the amino acid sequence shown as SEQ ID No. 12; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 50, HCDR2 of the amino acid sequence shown as SEQ ID NO. 51, HCDR3 of the amino acid sequence shown as SEQ ID NO. 52, LCDR1 of the amino acid sequence shown as SEQ ID NO. 53, LCDR2 of the amino acid sequence shown as QMS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 54;
HCDR1 of the amino acid sequence shown as SEQ ID NO. 15, HCDR2 of the amino acid sequence shown as SEQ ID NO. 16, HCDR3 of the amino acid sequence shown as SEQ ID NO. 17, LCDR1 of the amino acid sequence shown as SEQ ID NO. 18, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 19; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 29, HCDR2 of the amino acid sequence shown as SEQ ID NO. 30, HCDR3 of the amino acid sequence shown as SEQ ID NO. 31, LCDR1 of the amino acid sequence shown as SEQ ID NO. 32, LCDR2 of the amino acid sequence shown as STS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 33;
x. HCDR1 of the amino acid sequence shown as SEQ ID NO. 15, HCDR2 of the amino acid sequence shown as SEQ ID NO. 16, HCDR3 of the amino acid sequence shown as SEQ ID NO. 17, LCDR1 of the amino acid sequence shown as SEQ ID NO. 18, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 19; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 36, HCDR2 of the amino acid sequence shown as SEQ ID NO. 37, HCDR3 of the amino acid sequence shown as SEQ ID NO. 38, LCDR1 of the amino acid sequence shown as SEQ ID NO. 39, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 40;
HCDR1 of the amino acid sequence shown as SEQ ID NO. 15, HCDR2 of the amino acid sequence shown as SEQ ID NO. 16, HCDR3 of the amino acid sequence shown as SEQ ID NO. 17, LCDR1 of the amino acid sequence shown as SEQ ID NO. 18, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 19; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 43, HCDR2 of the amino acid sequence shown as SEQ ID NO. 44, HCDR3 of the amino acid sequence shown as SEQ ID NO. 45, LCDR1 of the amino acid sequence shown as SEQ ID NO. 46, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 47;
HCDR1 of the amino acid sequence shown as SEQ ID NO. 15, HCDR2 of the amino acid sequence shown as SEQ ID NO. 16, HCDR3 of the amino acid sequence shown as SEQ ID NO. 17, LCDR1 of the amino acid sequence shown as SEQ ID NO. 18, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 19; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 50, HCDR2 of the amino acid sequence shown as SEQ ID NO. 51, HCDR3 of the amino acid sequence shown as SEQ ID NO. 52, LCDR1 of the amino acid sequence shown as SEQ ID NO. 53, LCDR2 of the amino acid sequence shown as QMS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 54;
HCDR1 of the amino acid sequence shown as SEQ ID NO. 22, HCDR2 of the amino acid sequence shown as SEQ ID NO. 23, HCDR3 of the amino acid sequence shown as SEQ ID NO. 24, LCDR1 of the amino acid sequence shown as SEQ ID NO. 25, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 26; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 29, HCDR2 of the amino acid sequence shown as SEQ ID NO. 30, HCDR3 of the amino acid sequence shown as SEQ ID NO. 31, LCDR1 of the amino acid sequence shown as SEQ ID NO. 32, LCDR2 of the amino acid sequence shown as STS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 33;
HCDR1 of the amino acid sequence shown as SEQ ID NO. 22, HCDR2 of the amino acid sequence shown as SEQ ID NO. 23, HCDR3 of the amino acid sequence shown as SEQ ID NO. 24, LCDR1 of the amino acid sequence shown as SEQ ID NO. 25, LCDR2 of the amino acid sequence shown as AAS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 26; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 36, HCDR2 of the amino acid sequence shown as SEQ ID NO. 37, HCDR3 of the amino acid sequence shown as SEQ ID NO. 38, LCDR1 of the amino acid sequence shown as SEQ ID NO. 39, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 40;
xv. HCDR1 of the amino acid sequence shown in SEQ ID NO. 22, HCDR2 of the amino acid sequence shown in SEQ ID NO. 23, HCDR3 of the amino acid sequence shown in SEQ ID NO. 24, LCDR1 of the amino acid sequence shown in SEQ ID NO. 25, LCDR2 of the amino acid sequence shown in AAS and LCDR3 of the amino acid sequence shown in SEQ ID NO. 26; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 43, HCDR2 of the amino acid sequence shown as SEQ ID NO. 44, HCDR3 of the amino acid sequence shown as SEQ ID NO. 45, LCDR1 of the amino acid sequence shown as SEQ ID NO. 46, LCDR2 of the amino acid sequence shown as NAK and LCDR3 of the amino acid sequence shown as SEQ ID NO. 47; or (b)
xvi. HCDR1 of the amino acid sequence shown in SEQ ID NO. 22, HCDR2 of the amino acid sequence shown in SEQ ID NO. 23, HCDR3 of the amino acid sequence shown in SEQ ID NO. 24, LCDR1 of the amino acid sequence shown in SEQ ID NO. 25, LCDR2 of the amino acid sequence shown in AAS and LCDR3 of the amino acid sequence shown in SEQ ID NO. 26; and HCDR1 of the amino acid sequence shown as SEQ ID NO. 50, HCDR2 of the amino acid sequence shown as SEQ ID NO. 51, HCDR3 of the amino acid sequence shown as SEQ ID NO. 52, LCDR1 of the amino acid sequence shown as SEQ ID NO. 53, LCDR2 of the amino acid sequence shown as QMS and LCDR3 of the amino acid sequence shown as SEQ ID NO. 54.
15. The anti-drug antibody of any one of claims 1, 2 or 12 to 14, linked to one or more conjugate moieties.
16. The anti-drug antibody of claim 15, wherein the conjugate moiety comprises a clearance modifier, a toxin, a radioisotope, a DNA alkylating agent, a topoisomerase inhibitor, a tubulin binding agent, or other anti-cancer drug.
17. The anti-drug antibody of claim 15, wherein the conjugate moiety is covalently linked directly or through a linker.
18. A chimeric antigen receptor comprising the anti-drug antibody of any one of claims 1 to 14, a transmembrane region, and an intracellular signaling region.
19. The chimeric antigen receptor of claim 18, wherein the transmembrane region comprises a transmembrane region of CD3, CD4, CD8, or CD 28.
20. The chimeric antigen receptor according to claim 18, wherein the intracellular signaling region is selected from the group consisting of: an intracellular signal region sequence of CD3, fcyri, CD27, CD28, CD137, CD134, myD88, CD40, CD278, TLR, or a combination thereof.
21. The chimeric antigen receptor according to any one of claims 18-20, wherein the anti-drug antibody is a scFv.
22. The chimeric antigen receptor according to any one of claims 18 to 20, wherein the chimeric antigen receptor is transplanted into an allogeneic, autologous or xenogeneic cell.
23. The chimeric antigen receptor according to any one of claims 18 to 20, wherein the chimeric antigen receptor is transplanted into an immune effector cell.
24. The chimeric antigen receptor according to any one of claims 18 to 20, wherein the chimeric antigen receptor is transplanted into a T cell, a natural killer cell, a macrophage or a tumor-infiltrating lymphocyte.
25. A composition comprising the anti-drug antibody of any one of claims 1 to 17 or the chimeric antigen receptor of any one of claims 18 to 24, and one or more carriers.
26. An isolated polynucleotide encoding the anti-drug antibody of any one of claims 1 to 14 and/or the chimeric antigen receptor of any one of claims 18 to 24.
27. A vector comprising the isolated polynucleotide of claim 26.
28. A host expression system comprising the vector of claim 27, or having the polynucleotide of claim 27 integrated into its genome.
29. The host expression system of claim 28, which is a microorganism, yeast or mammalian cell, wherein the microorganism is selected from the group consisting of e.coli (e.coli) and b.subtilis; and wherein the mammalian cell is selected from the group consisting of: COS, CHO-S, CHO-K1, HEK-293 and 3T3 cells.
30. A virus comprising the vector of claim 27.
31. A method of expressing the anti-drug antibody of any one of claims 1 to 14 or the chimeric antigen receptor of any one of claims 18 to 24, the method comprising culturing the host expression system of claim 28 under conditions that express the anti-drug antibody of any one of claims 1 to 14 or the chimeric antigen receptor of any one of claims 18 to 24.
32. A method for detecting the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in a sample for non-diagnostic purposes, the method comprising contacting the sample with an anti-drug antibody according to any one of claims 1 to 17, and/or a chimeric antigen receptor according to any one of claims 18 to 24, and/or a composition according to claim 25, and determining the presence or amount of an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody in the sample.
33. The method of claim 32, wherein the method is used in a pharmacokinetic assay, a drug resistance assay, or a neutralization assay for an anti-PD-L1 antibody, an anti-4-1 BB antibody, or a bispecific PD-L1/4-1BB antibody.
34. A kit comprising the anti-drug antibody of any one of claims 1 to 17, and/or the chimeric antigen receptor of any one of claims 18 to 24, and/or the composition of claim 25.
35. Use of an anti-drug antibody according to any one of claims 1 to 17, and/or a chimeric antigen receptor according to any one of claims 18 to 24, and/or a composition according to claim 25 in the preparation of a kit, wherein the kit is used in a method for detecting an anti-PD-L1 antibody, an anti-4-1 BB antibody, or an anti-drug antibody (ADA) of a bispecific PD-L1/4-1BB antibody.
36. The method of claim 32 or 33, wherein the sample is selected from the group consisting of: paraffin-embedded tissues, body fluids, isolated blood cells, and any combination thereof.
37. The method of claim 36, wherein the anti-drug antibody of any one of claims 1 to 17 comprises a first antibody and a second antibody, wherein the first antibody comprises:
i. heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 1, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 2, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 3, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 4, the amino acid sequence of LCDR2 is shown in NAK, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 5;
heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 8, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 9, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 10, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 11, the amino acid sequence of LCDR2 is shown in RAN, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 12;
Heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 15, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 16, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 17, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 18, the amino acid sequence of LCDR2 is shown in AAS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 19; or (b)
Heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 22, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 23, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 24, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 25, the amino acid sequence of LCDR2 is shown in AAS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 26;
wherein the second antibody comprises:
i. heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO. 29, the amino acid sequence of HCDR2 is shown in SEQ ID NO. 30, the amino acid sequence of HCDR3 is shown in SEQ ID NO. 31, the amino acid sequence of LCDR1 is shown in SEQ ID NO. 32, the amino acid sequence of LCDR2 is shown in STS, and the amino acid sequence of LCDR3 is shown in SEQ ID NO. 33;
Heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO:36, the amino acid sequence of HCDR2 is shown as SEQ ID NO:37, the amino acid sequence of HCDR3 is shown as SEQ ID NO:38, the amino acid sequence of LCDR1 is shown as SEQ ID NO:39, the amino acid sequence of LCDR2 is shown as NAK, and the amino acid sequence of LCDR3 is shown as SEQ ID NO: 40;
heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO. 43, the amino acid sequence of HCDR2 is shown as SEQ ID NO. 44, the amino acid sequence of HCDR3 is shown as SEQ ID NO. 45, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 46, the amino acid sequence of LCDR2 is shown as NAK, and the amino acid sequence of LCDR3 is shown as SEQ ID NO. 47; or (b)
Heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequence of HCDR1 is shown as SEQ ID NO. 50, the amino acid sequence of HCDR2 is shown as SEQ ID NO. 51, the amino acid sequence of HCDR3 is shown as SEQ ID NO. 52, the amino acid sequence of LCDR1 is shown as SEQ ID NO. 53, the amino acid sequence of LCDR2 is shown as QMS, and the amino acid sequence of LCDR3 is shown as SEQ ID NO. 54.
38. The method of claim 37, wherein the bodily fluid is selected from the group consisting of: whole blood, serum, plasma, urine, mucus, saliva, peritoneal fluid, pleural fluid, synovial fluid, cerebrospinal fluid, pleural effusion, peritoneal effusion, and any combination thereof.
39. The method of claim 38, wherein the bispecific PD-L1/4-1BB antibody is ATG-101.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2022/090512 | 2022-04-29 | ||
CN2022090512 | 2022-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116120461A CN116120461A (en) | 2023-05-16 |
CN116120461B true CN116120461B (en) | 2023-09-29 |
Family
ID=86302607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310093475.9A Active CN116120461B (en) | 2022-04-29 | 2023-02-02 | Novel anti-drug antibodies and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116120461B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002419A1 (en) * | 2005-06-22 | 2007-01-04 | Prosetta Corporation | Conformer-specific antibodies and method of use, thereof |
WO2019196309A1 (en) * | 2018-04-09 | 2019-10-17 | 上海原能细胞医学技术有限公司 | Anti-pd-l1 antibody and use thereof |
CN112867507A (en) * | 2019-08-20 | 2021-05-28 | 科望(苏州)生物医药科技有限公司 | Novel anti-SIRPA antibodies |
CN112955468A (en) * | 2018-10-01 | 2021-06-11 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
WO2022015736A1 (en) * | 2020-07-13 | 2022-01-20 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019328632A1 (en) * | 2018-08-27 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof |
US20220025465A1 (en) * | 2018-11-14 | 2022-01-27 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing and treating cancer |
-
2023
- 2023-02-02 CN CN202310093475.9A patent/CN116120461B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002419A1 (en) * | 2005-06-22 | 2007-01-04 | Prosetta Corporation | Conformer-specific antibodies and method of use, thereof |
WO2019196309A1 (en) * | 2018-04-09 | 2019-10-17 | 上海原能细胞医学技术有限公司 | Anti-pd-l1 antibody and use thereof |
CN110869390A (en) * | 2018-04-09 | 2020-03-06 | 上海原能细胞医学技术有限公司 | anti-PD-L1 antibodies and uses thereof |
CN112955468A (en) * | 2018-10-01 | 2021-06-11 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
CN112867507A (en) * | 2019-08-20 | 2021-05-28 | 科望(苏州)生物医药科技有限公司 | Novel anti-SIRPA antibodies |
WO2022015736A1 (en) * | 2020-07-13 | 2022-01-20 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
Non-Patent Citations (1)
Title |
---|
ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation;Hui Yuwen等;Journal for ImmunoTherapy of Cancer(第9期);936-937 * |
Also Published As
Publication number | Publication date |
---|---|
CN116120461A (en) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016305697B2 (en) | Novel anti-PD-1 antibodies | |
AU2020286284B2 (en) | Novel anti-CD39 antibodies | |
WO2016197367A1 (en) | Novel anti-pd-l1 antibodies | |
WO2021032078A1 (en) | Novel anti-sirpa antibodies | |
KR20200055052A (en) | New anti-CD3 epsilon antibody | |
JP7554781B2 (en) | Anti-CEACAM5 monoclonal antibody, method for preparing same and use thereof | |
CA3074524A1 (en) | Novel anti-cd19 antibodies | |
WO2019179389A1 (en) | Novel anti-egfr antibody polypeptide | |
CN110305216B (en) | Novel anti-TIM-3 antibodies | |
WO2022063272A1 (en) | Novel anti-claudin18 antibodies | |
TW202313699A (en) | Novel anti-sirpa antibodies | |
CN116120461B (en) | Novel anti-drug antibodies and uses thereof | |
KR20230030626A (en) | Humanized antibody to Lewis Y | |
WO2023227062A1 (en) | Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
WO2023236891A1 (en) | Novel anti-lilrb4 antibodies and uses thereof | |
WO2024041315A1 (en) | Novel anti-lilrb2 antibodies and uses thereof | |
WO2023169419A1 (en) | Novel anti-cd3 antibodies and uses thereof | |
TW202413417A (en) | Novel anti-cd3 antibodies and uses thereof | |
CN118451105A (en) | Novel anti-IL-36R antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |